var docs;if (!docs) docs =[]; docs["59"]={"5900":"<p><b>Title</b> Fluticasone (Nasal) / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use of nasal fluticasone together with a strong CYP3A4 inhibitor is not recommended. Consider an alternative nasal corticosteroid when possible, particularly for longer-term concurrent use. Beclomethasone (and possibly some other steroids) may be less likely to have a clinically significant interaction. Some prescription fluticasone products specifically recommend against concurrent use with ritonavir and recommend only caution with other strong CYP3A4 inhibitors.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> According to fluticasone nasal inhalation prescribing information, concurrent use of a strong CYP3A4 inhibitor is not recommended due to evidence that concurrent use may lead to increased systemic steroid concentrations and effects,<sup>1</sup> but at least some products recommend only caution with most strong CYP3A4 inhibitors.<sup>2</sup> Concurrent use with the strong CYP3A4 inhibitor ritonavir is associated with both substantial increases in plasma fluticasone exposure (more than 100-fold) and an average 86% decrease in plasma cortisol concentrations.<sup>1</sup> A study with higher doses of orally inhaled fluticasone (1000 mcg via oral inhalation) and the strong CYP3A4 inhibitor ketoconazole (200 mg/day) found an average 1.9-fold increase in fluticasone AUC and an average 45% decrease in plasma cortisol concentrations.<sup>1</sup> One case report describes a 39-year-old male receiving chronic fluticasone nasal drops (800 mcg per day) who developed iatrogenic adrenal suppression 3 months after his rilpivirine/emtricitabine/tenofovir regimen was changed to one containing the strong CYP3A4 inhibitor cobicistat (elvitegravir/cobicistat/emtricitabine/tenofovir).<sup>3</sup> After treatment with hydrocortisone and a change from fluticasone to beclomethasone, his laboratory values normalized 3-6 weeks later.<sup>3</sup> Similarly, at least two published reports describe adrenal suppression/iatrogenic Cushing syndrome in patients receiving concurrent intranasal fluticasone and ritonavir.<sup>4,5</sup> As discussed in a review on the subject, several more cases have been reported with orally inhaled fluticasone and ritonavir.<sup>6</sup><br><br><br>A study with the moderate CYP3A4 inhibitor erythromycin found no significant change in fluticasone concentrations.<sup>1</sup><br><br>Fluticasone is a CYP3A substrate, suggesting that the mechanism for this interaction is impairment of fluticasone metabolism, resulting in increased fluticasone serum concentrations and increased fluticasone effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Fluticasone nasal spray [prescribing information]. Morton Grove, IL: Morton Grove Pharmaceuticals, Inc.; March 2016.</p>\n<p>2. Dymista (azelastine and fluticasone) nasal spray [prescribing information]. Somerset, NJ: Meda Pharmaceuticals; February 2015.</p>\n<p>3. Lewis J, Turtle L, Khoo S, Nsutebu EN. A case of iatrogenic adrenal suppression after co-administration of cobicistat and fluticasone nasal drops. <i>AIDS</i>. 2014;28(17);2636-2637. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25574967\">[PubMed 25574967]</a></p>\n<p>4. Chen F, Kearney T, Robinson S, et al. Cushing's syndrome and severe adrenal suppression in patients treated with ritonavir and inhaled nasal fluticasone. <i>Sex Transm Infect</i>. 1999;75(4):274. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10615321\">[PubMed 10615321]</a></p>\n<p>5. Hillebrand-Haverkort ME, Prummel MF, ten Veen JH. Ritonavir-induced Cushing's syndrome in a patient treated with nasal fluticasone. <i>AIDS</i>. 1999;13(13):1803. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10509596\">[PubMed 10509596]</a></p>\n<p>6. Foisy MM, Yakiwchuk EM, Chiu I, et al. Adrenal suppression and Cushing's syndrome secondary to an interaction between ritonavir and fluticasone: A review of the literature. <i>HIV Med</i>. 2008;9(6):389-396. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18459946\">[PubMed 18459946]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5901":"<p><b>Title</b> Fluticasone (Oral Inhalation) / CYP3A4 Inhibitors (Strong)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Brand Name</b>: The warnings with fluticasone propionate (Flovent HFA) are more severe than are the ones with fluticasone furoate/vilanterol (Breo Ellipta).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of orally inhaled fluticasone propionate with strong CYP3A4 inhibitors is not recommended. Use of orally inhaled fluticasone furoate with strong CYP3A4 inhibitors should be done with caution, and patients using such a combination should be monitored more closely for evidence of systemic corticosteroid toxicities.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The fluticasone AUC increased nearly 2-fold when orally inhaled fluticasone propionate (1000 mcg) was given with the strong CYP3A4 inhibitor ketoconazole (200 mg/day) in a study of 8 healthy volunteers.<sup>1</sup> Plasma cortisol AUC decreased by an average of 45% with the combination. Of note, a study with aqueous nasally inhaled fluticasone propionate found that fluticasone AUC increased more than 100-fold when nasally inhaled fluticasone propionate (200 mcg/day) was given with the strong CYP3A4 inhibitor ritonavir (100 mg twice/day) for 7 days (n=18 healthy volunteers).<sup>1</sup> In these subjects, plasma cortisol AUC was reduced by an average of 86%. Based on these findings, the fluticasone propionate oral inhalation prescribing information states that concurrent use of a strong CYP3A4 inhibitor is not recommended due to evidence that concurrent use is associated with both increases in plasma fluticasone exposure and decreases in plasma cortisol concentrations.<sup>1</sup><br><br>The fluticasone AUC increased by an average of 36% when fluticasone furoate/vilanterol (200 mcg/25 mcg once/day x 7 days) was given with ketoconazole (400 mg/day x 11 days).<sup>2</sup> Average plasma cortisol was 27% lower with use of the combination. The fluticasone furoate/vilanterol oral inhalation prescribing information recommends caution when considering use with a strong CYP3A4 inhibitors.<sup>3</sup><br><br>Fluticasone is a CYP3A substrate, suggesting that the mechanism for this interaction is impairment of fluticasone metabolism, resulting in increased fluticasone serum concentrations and increased systemic fluticasone effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Flovent HFA (fluticasone propionate). Research Triangle Park, NC: GlaxoSmithKline, 01/2012.</p>\n<p>2. Kempsford R, Allen A, Bal J, et al, “The Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Inhaled Fluticasone Furoate and Vilanterol Trifenatate in Healthy Subjects,” <i>Br J Clin Pharmacol</i>, 2013, 75(6):1478-87. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23116485\">[PubMed 23116485]</a></p>\n<p>3. Prescribing information. Breo Ellipta (fluticasone furoate/vilanterol). Research Triangle Park, NC: GlaxoSmithKline, May 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5902":"<p><b>Title</b> Budesonide (Nasal) / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor response to budesonide nasal inhalation closely when used with a strong CYP3A4 inhibitor. In particular, monitor patients for signs/symptoms of excessive corticosteroid concentrations (i.e., Cushing's-type signs/symptoms).</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> Although specific studies with budesonide nasal inhalation are not available, the prescribing information information recommends caution with concurrent use of any strong CYP3A4 inhbitor based on interaction data with orally administered budesonide that show an increase in systemic budesonide exposure with concurrent use of the the strong CYP3A4 inhibitor ketoconazole.<sup>1</sup><br><br>Two separate published case reports describe patients being treated with orally inhaled budesonide who developed Cushing's syndrome with concurrent use of the strong CYP3A4 inhibitors itraconazole in one case,<sup>2</sup> and ritonavir in the other case.<sup>3</sup> Another case report describes a patient receiving oral budesonide who developed Cushing's syndrome with concurrent use of ritonavir and atazanavir, both of which are strong CYP3A4 inhibitors.<sup>4</sup><br><br>The average AUC and maximum serum concentration (Cmax) of budesonide were increased an average of 4.2- and 1.6-fold, respectively, when orally inhaled budesonide (1000 mcg) was administered with the strong CYP3A4 inhibitor itraconazole (200 mg/day x 5 days) in a study of 10 healthy volunteers.<sup>5</sup> The average elimination half-life of budesonide was increased from 1.6 hours to 6.2 hours with concurrent itraconazole, and the average plasma cortisol concentration was decreased by 43%, demonstrating the clinical significance of the increased budesonide concentrations.<br><br>The likely mechanism of this interaction is inhibition of the CYP3A4 (intestinal and hepatic) metabolism of budesonide, which is a CYP3A substrate, by strong CYP3A4 inhibitors such as itraconazole and ritonavir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Rhinocort Aqua (budesonide). Wilmington, DE: AstraZeneca LP, 12/10.</p>\n<p>2. Bolland MJ, Bagg W, Thomas MG, et al, “Cushing's Syndrome Due to Interaction between Inhaled Corticosteroids and Itraconazole,” <i>Ann Pharmacother</i>, 2004, 38(1):46-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14742792\">[PubMed 14742792]</a></p>\n<p>3. Kedem E, Shahar E, Hassoun G, et al, “Iatrogenic Cushing's Syndrome Due to Coadministration of Ritonavir and Inhaled Budesonide in an Asthmatic Human Immunodeficiency Virus Infected Patient,” <i>J Asthma</i>, 2010, 47(7):830-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20653496\">[PubMed 20653496]</a></p>\n<p>4. Frankel JK, Packer CD, “Cushing's Syndrome Due to Antiretroviral-Budesonide Interaction,” <i>Ann Pharmacother</i>, 2011, 10 May (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21558486\">[PubMed 21558486]</a></p>\n<p>5. Raaska K, Niemi M, Neuvonen M, et al, “Plasma Concentrations of Inhaled Budesonide and Its Effects on Plasma Cortisol are Increased by the Cytochrome P4503A4 Inhibitor Itraconazole,” <i>Clin Pharmacol Ther</i>, 2002, 72(4):362-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12386638\">[PubMed 12386638]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5906":"<p><b>Title</b> Voriconazole / Fluconazole</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Fluconazole may increase the serum concentration of Voriconazole. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of fluconazole and voriconazole. Dose reductions and changes in dosing frequency were not effective at minimizing the significance of this interaction. Due to the long half-life of fluconazole, caution is also recommended with sequential use of voriconazole after fluconazole, and particularly when voriconazole is used within 24 hours of fluconazole discontinuation. Such patients should be monitored closely for signs/symptoms of voriconazole toxicity.</p> \n<p><b>Discussion</b> The average voriconazole AUC and maximum serum concentration (Cmax) were increased by 79% and 57%, respectively, when voriconazole (400 mg every 12 hours x 1 day, then 200 mg every 12 hours x 2.5 days) was administered to 6 healthy volunteers who were also receiving fluconazole (400 mg/day x 1 day, then 200 mg/day x 4 days).<sup>1</sup> In a follow-up study of 8 healthy volunteers, attempts to minimize the significance of this interaction by lowering the dose and/or altering the administration frequency were unsuccessful. As a result, fluconazole prescribing information recommends avoiding concurrent use with voriconazole, and the prescribing information also recommends caution when voriconazole is used after discontinuation of fluconazole, since the enzyme inhibiting effects of fluconazole are estimated to persist for up to 4-5 days after fluconazole discontinuation due to its approximately 30-hour half-life in most adults.<sup>1</sup><br><br>The likely mechanism of this interaction is fluconazole-mediated inhibition of the CYP2C9 and CYP3A4 metabolism of voriconazole.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Diflucan (fluconazole). New York, NY: Pfizer Inc, April 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5916":"<p><b>Title</b> CYP2D6 Substrates (High risk with Inhibitors) / Abiraterone Acetate</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Abiraterone Acetate may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible. When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity related to the CYP2D6 substrate (or decreased effects if the drug is a prodrug activated by CYP2D6).</p>\n<div>\n <p><b>CYP2D6 Substrates (High risk with Inhibitors) Interacting Members</b> Ajmaline, Amitriptyline, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, AtoMOXetine, Brexpiprazole, Captopril, Carvedilol, Chloroquine, Chlorpheniramine, ChlorproMAZINE, ClomiPRAMINE, Codeine, Dapoxetine, Desipramine, Deutetrabenazine, Dextromethorphan, Doxepin (Systemic), Doxepin (Topical), DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Eliglustat, Flecainide, FLUoxetine, FluPHENAZine, FluvoxaMINE, Gefitinib, Haloperidol, Iloperidone, Imipramine, Indoramin, Maprotiline, Mequitazine, Methamphetamine, Metoprolol, Mexiletine, Mirtazapine, Nefazodone, Nortriptyline, Olmutinib, PARoxetine, Perhexiline, Perphenazine, Pimozide, Primaquine, Procainamide, Propafenone, Propranolol, Protriptyline, RisperiDONE, Syrian Rue, Tamoxifen, Tetrabenazine, Thioridazine, Timolol (Ophthalmic), Timolol (Systemic), Tolterodine, Trimipramine, Tropisetron, Venlafaxine, Vortioxetine, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> As described in the abiraterone prescribing information, the AUC of the CYP2D6 substrate dextromethorphan increased an average of 2.9-fold with concurrent abiraterone (1000 mg/day, with prednisone 5 mg twice/day).<sup>1</sup> The dextromethorphan maximum serum concentration (Cmax) also increased by an average of 2.8-fold with abiraterone. These findings support the results of in vitro studies that concluded abiraterone was a strong inhibitor of CYP2D6 in human liver microsomes.<sup>1</sup><br><br>As a result of these data, the abiraterone prescribing information recommends avoiding concurrent use of abiraterone with any CYP2D6 substrate that has a narrow therapeutic index.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Zytiga (abiraterone acetate). Horsham, PA: Centocor Ortho Biotech Inc., April 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5917":"<p><b>Title</b> CYP1A2 Substrates (High risk with Inhibitors) / Abiraterone Acetate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Abiraterone Acetate may increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor clinical response to any CYP1A2 substrate closely when used with abiraterone. In particular, monitor patients for signs/symptoms associated with increased concentrations of the CYP1A2 substrate.</p>\n<div>\n <p><b>CYP1A2 Substrates (High risk with Inhibitors) Interacting Members</b> Acebrophylline, Acenocoumarol, Agomelatine, Alosetron, Aminophylline, Asenapine, Bromazepam, Caffeine, ClomiPRAMINE, CloZAPine, Cyclobenzaprine, Dacarbazine, DULoxetine, Flutamide, FluvoxaMINE, Kola Nut, Lidocaine (Systemic), Lidocaine (Topical), Melatonin, Mexiletine, Mirtazapine, OLANZapine, Pimozide, Pirfenidone, Pomalidomide, Propranolol, Ramelteon, Ramosetron, Rasagiline, ROPINIRole, Ropivacaine, Stiripentol, Tasimelteon, Theophylline, Thiothixene, TiZANidine, Trifluoperazine</p>\n</div> \n<p><b>Discussion</b> According to abiraterone prescribing information, in vitro studies in human liver microsomes concluded that abiraterone is a strong inhibitor of CYP1A2.<sup>1</sup> In contrast, the AUC of theophylline, a CYP1A2 substrate, was not significantly changed when a single dose of theophylline (100 mg) was administered to individuals receiving abiraterone (1000 mg/day, plus prednisone 5 mg twice/day).<sup>1</sup> It is unclear whether this clinical finding suggests the in vitro data are not clinically relevant or is primarily the result of study design issues such as the use of a single theophylline dose, concurrent prednisone, specific population studied, or other such confounding/modifying factors.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Zytiga (abiraterone acetate). Horsham, PA: Centocor Ortho Biotech Inc., April 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5919":"<p><b>Title</b> CycloSPORINE (Systemic) / Tigecycline</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Tigecycline may increase the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor cyclosporine concentrations closely following the initiation and/or discontinuation of concurrent tigecycline. Also monitor patients for signs/symptoms of cyclosporine toxicity during concurrent therapy.</p> \n<p><b>Discussion</b> A case report describes a 61-year-old female who experienced an acute increase in serum cyclosporine concentration following the initiation of tigecycline.<sup>1</sup> This led to a 50% reduction in her cyclosporine dose for the remaining duration of concurrent therapy, with her cyclosporine dose increased back to the original (pre-tigecycline) dose following cessation of tigecycline. Also, the patient's serum creatinine also increased during concurrent therapy, in what the case report authors ascribe to cyclosporine nephrotoxic effects. Of note, the cyclosporine concentrations appeared to be elevated (vs. the end-of-tigecycline therapy concentrations) and somewhat variable immediately prior to tigecycline, with values of approximately 275-400 ng/mL recorded in the 3 days prior to tigecycline and on day 1 of tigecycline therapy. The maximum cyclosporine concentration (approximately 600 ng/mL) was recorded on day 4 of concurrent therapy and rapidly declined to around 300 ng/mL by days 6-7 of therapy (after a 50% reduction in cyclosporine dose) and then to approximately 150 ng/mL by days 11-13 of concurrent therapy and after tigecycline cessation. This pattern of cyclosporine concentration changes, and particularly the apparently elevated concentrations prior to tigecycline therapy, raise some questions about the possible role of other (perhaps disease/comorbidity-related?) issues in the observed increases in cyclosporine concentrations.<br><br>The specific mechanism(s) for this interaction is/are unclear. Tigecycline is not a known inhibitor of the CYP3A enzyme,<sup>2</sup> which is primarily responsible for cyclosporine metabolism, and it is not a known inhibitor of transporters, such as p-glycoprotein,<sup>2</sup> that are known to alter cyclosporine disposition. Despite the finding that tigecycline did not significantly alter the disposition of digoxin, a substrate for p-glycoprotein, changes in the p-glycoprotein-mediated transport of cyclosporine have been suggested as one possible mechanism.<sup>1,3</sup> Direct competition for biliary excretion, where tigecycline competitively inhibits the excretion of cyclosporine, has also be suggested as a possible mechanism.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Stumpf AN, Schmidt C, Hiddemann W, et al, “High Serum Concentrations of Cyclosporin Related to Administration of Tigecycline,” <i>Eur J Clin Pharmacol</i>, 2009, 65(1):101-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18795273\">[PubMed 18795273]</a></p>\n<p>2. Prescribing information. Tygacil (tigecycline). Philadelphia, PA: Wyeth Pharmaceuticals Inc., January 2011.</p>\n<p>3. Srinivas NR, “Tigecycline and Cyclosporine Interaction-An Interesting Case of Biliary-Excreted Drug Enhancing the Oral Bioavailability of Cyclosporine,” <i>Eur J Clin Pharmacol</i>, 2009, 65(5):543-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19224202\">[PubMed 19224202]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5921":"<p><b>Title</b> Gabapentin / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antacids may decrease the serum concentration of Gabapentin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Administer gabapentin at least 2 hours after antacid administration. Monitor patients closely for evidence of reduced response to gabapentin therapy when both of these drugs are being used.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> The impact of magnesium oxide (MgO) and omeprazole on gabapentin bioavailability was evaluated in an open-label, randomized, 3-period crossover study in 13 healthy male subjects.<sup>1</sup> Subjects were given a single dose of gabapentin 200mg alone, with 1g of MgO administered simultaneously, or with 20mg of omeprazole, administered 12 hours and 30 minutes before the gabapentin. Systemic exposure was significantly reduced with co-administration of MgO compared to gabapentin alone with a decrease in bioavailability of 32%. Omeprazole did not have a significant effect on the bioavailability of gabapentin.<br><br>According to gabapentin prescribing information, concurrent administration of gabapentin and Maalox-brand antacid was associated with an average 20% decrease in gabapentin bioavailability in a study of 16 healthy volunteers.<sup>2</sup> When gabapentin was given 2 hours after the antacid, the average reduction in gabapentin bioavailability was only 5%, leading to the recommendation that gabapentin should be administered at least 2 hours after administration of Maalox-brand antacid. Of note, the prescribing information does not identify which specific antacid product (i.e., calcium carbonate vs. aluminum hydroxide/magnesium hydroxide) was used in this study. Until further information is available, this recommendation is likely applicable to all antacid products.<br><br>The mechanism for this interaction is uncertain although it does not appear to be related to an increase in gastric pH. Formation of a chelate complex is a possible mechanism for this interaction but this has not been clearly established.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Yagi T, Naito Y, Mino Y, Umemura K, Kawakami J. Impact of concomitant antacid administration on gabapentin plasma exposure and oral bioavailability in healthy adult subjects. <i>Drug Metab Pharmacokinet</i>. 2012;27(2):248-54. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22240839\">[PubMed 22240839]</a></p>\n<p>2. Prescribing information. Neuronin (gabapentin). New York, NY: Pfizer Inc, 5/2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5922":"<p><b>Title</b> Gabapentin / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of Gabapentin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Gabapentin AUC was an average of 24% higher following coadministration of the gabapentin prodrug gabapentin enacarbil (1200 mg once daily) and cimetidine (400 mg four times/day).<sup>1</sup> The renal clearance of gabapentin was reduced by an average of 20%. A separate study also reported an average 14% reduction in gabapentin renal clearance with concurrent administration of cimetidine (300 mg four times/day).<sup>2</sup> This relatively small increase in gabapentin exposure is unlikely to be of clinical relevance.<sup>1,2</sup><br><br>The mechanism for this interaction appears to be cimetidine-mediated inhibition of the organic cation transporter-2 (OCT2) transporter, which is involved in the renal excretion of gabapentin.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Horizant (gabapentin enacarbil). Research Triangle Park, NC: GlaxoSmithKline, April 2011.</p>\n<p>2. Prescribing information. Neuronin (gabapentin). New York, NY: Pfizer Inc, July 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5923":"<p><b>Title</b> Gabapentin Enacarbil / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Cimetidine may increase serum concentrations of the active metabolite(s) of Gabapentin Enacarbil. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Gabapentin AUC was an average of 24% higher following coadministration of the gabapentin prodrug gabapentin enacarbil (1200 mg once daily) and cimetidine (400 mg four times/day).<sup>1</sup> The renal clearance of gabapentin was reduced by an average of 20%. A separate study also reported an average 14% reduction in gabapentin renal clearance with concurrent administration of cimetidine (300 mg four times/day).<sup>2</sup> This relatively small increase in gabapentin exposure is unlikely to be of clinical relevance.<sup>1,2</sup><br><br>The mechanism for this interaction appears to be cimetidine-mediated inhibition of the organic cation transporter-2 (OCT2) transporter, which is involved in the renal excretion of gabapentin.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Horizant (gabapentin enacarbil). Research Triangle Park, NC: GlaxoSmithKline, April 2011.</p>\n<p>2. Prescribing information. Neuronin (gabapentin). New York, NY: Pfizer Inc, July 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5924":"<p><b>Title</b> Quinolones / Lanthanum</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): This interaction is only expected with oral administration of quinolone antibiotics.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Lanthanum may decrease the serum concentration of Quinolones. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Administer oral quinolone antibiotics at least one hour before or four hours after lanthanum.</p>\n<div>\n <p><b>Quinolones Interacting Members</b> Ciprofloxacin (Systemic), Delafloxacin, LevoFLOXacin (Systemic), Moxifloxacin (Systemic), Nalidixic Acid, Norfloxacin, Ofloxacin (Systemic), Pefloxacin, Pipemidic Acid, Sparfloxacin<br><b>Exceptions</b> Gemifloxacin, LevoFLOXacin (Oral Inhalation), Lomefloxacin</p>\n</div> \n<p><b>Discussion</b> Per lanthanum prescribing information, quinolone antibiotics should be administered at least one hour before or four hours after lanthanum administration due to a risk of adsorption in the gastrointestinal tract.<sup>1</sup> In a clinical study of 12 healthy volunteers, administration of ciprofloxacin (750 mg single dose) immediately after a dose of lanthanum carbonate (1 g) decreased ciprofloxacin maximum concentration and AUC by 56% and 54%, respectively.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Fosrenol (lanthanum) [prescribing information]. Lexington, MA: Shire US Inc.; February 2016.</p>\n<p>2. How PP, Fischer JH, Arruda JA, et al. Effects of lanthanum carbonate on the absorption and oral bioavailability of ciprofloxacin. <i>Clin J Am Soc Nephrol</i>. 2007;2(6):1235-1240. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17913970\">[PubMed 17913970]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5925":"<p><b>Title</b> Tetracyclines / Lanthanum</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): This interaction is only expected with oral administration of tetracycline antibiotics.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Lanthanum may decrease the serum concentration of Tetracyclines. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Administer oral tetracycline antibiotics at least two hours before or after lanthanum.</p>\n<div>\n <p><b>Tetracyclines Interacting Members</b> Demeclocycline, Doxycycline, Lymecycline, Minocycline, Oxytetracycline, Tetracycline (Systemic)</p>\n</div> \n<p><b>Discussion</b> Per lanthanum prescribing information, compounds such as tetracycline antibiotics that may bind to cationic antacids should not be administered within 2 hours of lanthanum due to a risk of adsorption in the gastrointestinal tract.<sup>1</sup> No such effects have been demonstrated clinically, but in vitro data indicate some capacity for tetracycline adsorption by lanthanum,<sup>2</sup> and clinical data with ciprofloxacin suggest that a clinically significant adsorption interaction may be possible.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Fosrenol (lanthanum carbonate). Wayne, PA, Shire US Inc., 4/2011.</p>\n<p>2. Vu BK, Snisarenko O, Lee HS, et al, “Adsorption of Tetracycline on La-Impregnated MCM-41 Materials,” <i>Environ Technol</i>, 2010, 31(3):233-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20426265\">[PubMed 20426265]</a></p>\n<p>3. How PP, Fischer JH, Arruda JA, et al, “Effects of Lanthanum Carbonate on the Absorption and Oral Bioavailability of Ciprofloxacin,” <i>Clin J Am Soc Nephrol</i>, 2007, 2(6):1235-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17913970\">[PubMed 17913970]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5926":"<p><b>Title</b> Ampicillin / Lanthanum</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): This interaction is only expected with oral administration of ampicillin.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Lanthanum may decrease the serum concentration of Ampicillin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Administer oral ampicillin at least two hours before or after lanthanum.</p> \n<p><b>Discussion</b> Per lanthanum prescribing information, compounds such as ampicillin that may bind to cationic antacids should not be administered within 2 hours of lanthanum due to a risk of adsorption in the gastrointestinal tract.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Fosrenol (lanthanum carbonate) [prescribing information]. Wayne, PA: Shire US Inc; April 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5927":"<p><b>Title</b> Astemizole / Delavirdine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Delavirdine may enhance the arrhythmogenic effect of Astemizole. Delavirdine may increase the serum concentration of Astemizole. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of delavirdine with astemizole is contraindicated.</p> \n<p><b>Discussion</b> According to delavirdine prescribing information, concurrent use of delavirdine with astemizole is contraindicated due to the potential for delavirdine to increase astemizole concentrations and the risk for serious proarrhythmic effects.<sup>1</sup><br><br>The specific mechanism for this potential interaction is likely delavirdine inhibition of the CYP3A-mediated metabolism of astemizole.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Rescriptor (delavirdine). New York, NY: Pfizer Inc, May 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5928":"<p><b>Title</b> Terfenadine / Delavirdine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Delavirdine may enhance the arrhythmogenic effect of Terfenadine. Delavirdine may increase the serum concentration of Terfenadine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of delavirdine with terfenadine is contraindicated.</p> \n<p><b>Discussion</b> According to delavirdine prescribing information, concurrent use of delavirdine with terfenadine is contraindicated due to the potential for delavirdine to increase terfenadine concentrations and the risk for serious proarrhythmic effects.<sup>1</sup><br><br>The specific mechanism for this potential interaction is likely delavirdine inhibition of the CYP3A-mediated metabolism of terfenadine.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Rescriptor (delavirdine). New York, NY: Pfizer Inc, May 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5929":"<p><b>Title</b> Thyroid Products / Lanthanum</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): Route (oral): This interaction is only expected with oral administration of thyroid products.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Lanthanum may decrease the serum concentration of Thyroid Products. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Administer oral thyroid products at least two hours before or after lanthanum.</p>\n<div>\n <p><b>Thyroid Products Interacting Members</b> Levothyroxine, Liothyronine, Liotrix, Thyroid, Desiccated</p>\n</div> \n<p><b>Discussion</b> Per lanthanum prescribing information, compounds such as thyroid hormones that may bind to cationic antacids should not be administered within 2 hours of lanthanum due to a risk of adsorption in the gastrointestinal tract.<sup>1</sup> Adsorption of levothyroxine by aluminum hydroxide has been demonstrated in vitro,<sup>2,3</sup> and clinical data in healthy volunteers indicate a roughly 40% decrease in levothyroxine bioavailability and AUC with simultaneous coadministration of lanthanum.<sup>1,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Synthroid (levothyroxine sodium). North Chicago, IL: Abbott Laboratories, 5/2009.</p>\n<p>2. Mersebach H, Rasmussen AK, Kirkegaard L, et al, “Intestinal Adsorption of Levothyroxine by Antacids and Laxatives: Case Stories and In Vitro Experiments,” <i>Pharmacol Toxicol</i>, 1999, 84(3):107-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10193669\">[PubMed 10193669]</a></p>\n<p>3. Liel Y, Sperber AD and Shany S, “Nonspecific Intestinal Adsorption of Levothyroxine by Aluminum Hydroxide,” <i>Am J Med</i>, 1994, 97(4):363-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7942938\">[PubMed 7942938]</a></p>\n<p>4. Weitzman SP, Ginsburg KC and Carlson HE, “Colesevelam Hydrochloride and Lanthanum Carbonate Interfere With the Absorption of Levothyroxine,” <i>Thyroid</i>, 2009, 19(1):77-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19119983\">[PubMed 19119983]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5930":"<p><b>Title</b> Angiotensin-Converting Enzyme Inhibitors / Lanthanum</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Lanthanum may decrease the serum concentration of Angiotensin-Converting Enzyme Inhibitors. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Administer angiotensin-converting enzyme inhibitors at least two hours before or after lanthanum.</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril, Cilazapril, Enalapril, Fosinopril, Imidapril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Zofenopril<br><b>Exception</b> Enalaprilat</p>\n</div> \n<p><b>Discussion</b> Per lanthanum prescribing information, compounds such as angiotensin-converting enzyme inhibitors that may bind to cationic antacids should not be administered within 2 hours of lanthanum due to a risk of adsorption in the gastrointestinal tract.<sup>1</sup> Apparent antacid binding interactions have been demonstrated clinically with captopril and fosinopril.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Fosrenol (lanthanum carbonate). Wayne, PA, Shire US Inc., 4/2011.</p>\n<p>2. Mantyla R, Mannisto PT, Vuorela, A, et al, “Impairment of Captopril Bioavailability by Concomitant Food and Antacid Intake,” <i>Int J Clin Pharmacol Ther Toxicol</i>, 1984, 22(11):626-9.</p>\n<p>3. Moore L, Kramer A, Swites B, et al, “Effect of Cimetidine and Antacid on the Kinetics of the Active Diacid of Fosinopril in Healthy Subjects,” <i>J Clin Pharmacol</i>, 1988, 28:946-59.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5931":"<p><b>Title</b> Lanthanum / HMG-CoA Reductase Inhibitors (Statins)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> HMG-CoA Reductase Inhibitors (Statins) may decrease the serum concentration of Lanthanum. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Administer HMG-CoA reductase inhibitors at least two hours before or after lanthanum.</p>\n<div>\n <p><b>HMG-CoA Reductase Inhibitors (Statins) Interacting Members</b> AtorvaSTATin, Fluvastatin, Lovastatin, Pitavastatin, Pravastatin, Red Yeast Rice, Rosuvastatin, Simvastatin</p>\n</div> \n<p><b>Discussion</b> Per lanthanum prescribing information, compounds such as HMG-CoA reductase inhibitors that may bind to cationic antacids should not be administered within 2 hours of lanthanum due to a risk of adsorption in the gastrointestinal tract.<sup>1</sup> Apparent antacid binding interactions have been demonstrated clinically with rosuvastatin and atorvastatin.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Fosrenol (lanthanum carbonate). Wayne, PA, Shire US Inc., 4/2011.</p>\n<p>2. Martin PD, Schneck DW, Dane AL, Warwick MJ, “The Effect of a Combination Antacid Preparation Containing Aluminum Hydroxide and Magnesium Hydroxide on Rosuvastatin Pharmacokinetics,” <i>Curr Med Res Opin,</i> 2008, 24(4):1231-5.</p>\n<p>3. Yang BB, Smithers JA, Abel RS, et al, “Effects of Maalox TC on Pharmacokinetics and Pharmacodynamics of Atorvastatin,” <i>Pharm Res</i>, 1996, 13(Suppl 9):S437 [abstract].</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5932":"<p><b>Title</b> Chloroquine / Lanthanum</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Lanthanum may decrease the serum concentration of Chloroquine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Administer chloroquine at least two hours before or after lanthanum.</p> \n<p><b>Discussion</b> Per lanthanum prescribing information, compounds that may bind to cationic antacids should not be administered within 2 hours of lanthanum due to a risk of adsorption in the gastrointestinal tract.<sup>1</sup> Antimalarial drugs are specifically mentioned as potentially interacting members, and both in vitro<sup>2,3</sup> and clinical<sup>4</sup> data suggest that chloroquine may be significantly adsorbed by antacids.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Fosrenol (lanthanum carbonate). Wayne, PA, Shire US Inc., 4/2011.</p>\n<p>2. McElnay JC, Mukhtar HA, D'Arcy PF, et al, “The Effect of Magnesium Trisilicate and Kaolin on the In Vivo Absorption of Chloroquine,” <i>J Trop Med Hyg</i>, 1982, 85(4):159-63. [PMID: 6292443]</p>\n<p>3. McElnay JC, Mukhtar HA, D'Arcy PF, et al, “In Vitro Experiments on Chloroquine and Pyrimethamine Absorption in the Presence of Antacid Constituents or Kaolin,” <i>J Trop Med Hyg</i>, 1982, 85(4):153-8. [PMID: 7143531]</p>\n<p>4. Iwuagwu MA, Aloko KS, “Adsorption of Paracetamol and Chloroquine Phosphate by Some Antacids,” <i>J Pharm Pharmacol</i>, 1992, 44(8):655-8. [PMID: 1359089]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5933":"<p><b>Title</b> Halofantrine / Lanthanum</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Lanthanum may decrease the serum concentration of Halofantrine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Administer halofantrine at least two hours before or after lanthanum.</p> \n<p><b>Discussion</b> Per lanthanum prescribing information, compounds that may bind to cationic antacids should not be administered within 2 hours of lanthanum due to a risk of adsorption in the gastrointestinal tract.<sup>1</sup> Antimalarial drugs are specifically mentioned as potentially interacting members, and clinical data suggest that halofantrine may be significantly adsorbed by antacids.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Fosrenol (lanthanum carbonate). Wayne, PA, Shire US Inc., 4/2011.</p>\n<p>2. Aideloje SO, Onyeji CO, and Ugwu NC, “Altered Pharmacokinetics of Altered Halofantrine by an Antacid, Magnesium Carbonate,” <i>Eur J Pharm Biopharm</i>, 1998, 46(3):299-303. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9885302\">[PubMed 9885302]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5934":"<p><b>Title</b> Meperidine / HydrOXYzine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> HydrOXYzine may enhance the CNS depressant effect of Meperidine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider a decrease in meperidine dose, as appropriate, when used together with hydroxyzine. With concurrent use, monitor patients closely for excessive response to the combination.</p> \n<p><b>Discussion</b> Hydroxyzine prescribing information cautions that hydroxyzine may potentiate the effects of meperidine, particularly when these drugs are used together as premedication and/or following general anesthesia.<sup>1</sup> Consequently, the dosing/use of meperidine may need to be adjusted when used with hydroxyzine.<br><br>The specific mechanism(s) for this interaction is/are not clear, but both hydroxyzine and meperidine are known to possess CNS depressant effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Vistaril (hydroxyzine). New York, NY: Pfizer Inc, April 2004.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5935":"<p><b>Title</b> Barbiturates / HydrOXYzine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> HydrOXYzine may enhance the CNS depressant effect of Barbiturates. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider a decrease in the barbiturate dose, as appropriate, when used together with hydroxyzine. With concurrent use, monitor patients closely for excessive response to the combination.</p>\n<div>\n <p><b>Barbiturates Interacting Members</b> Amobarbital, Butabarbital, Butalbital, Methohexital, PENTobarbital, PHENobarbital, Primidone, Secobarbital, Thiopental</p>\n</div> \n<p><b>Discussion</b> Hydroxyzine prescribing information cautions that hydroxyzine may potentiate the effects of barbiturates, particularly when these drugs are used together as premedication and/or following general anesthesia.<sup>1</sup> Consequently, the dosing/use of the barbiturate may need to be adjusted when used with hydroxyzine.<br><br>The specific mechanism(s) for this interaction is/are not clear, but both hydroxyzine and barbiturates are known to possess CNS depressant effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Vistaril (hydroxyzine). New York, NY: Pfizer Inc, April 2004.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5936":"<p><b>Title</b> CNS Depressants / HydrOXYzine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> HydrOXYzine may enhance the CNS depressant effect of CNS Depressants. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant. A reduction in the dose of any other CNS depressants that are to be used in combination may be warranted.</p>\n<div>\n <p><b>CNS Depressants Interacting Members</b> Acrivastine, Afloqualone, Alcohol (Ethyl), Alfentanil, ALPRAZolam, Amisulpride, Amitriptyline, Amobarbital, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Baclofen, Benperidol, Benzhydrocodone, Bilastine, Blonanserin, Brexpiprazole, Brimonidine (Ophthalmic), Brivaracetam, Bromazepam, Bromperidol, Brompheniramine, Buclizine, Buprenorphine, BusPIRone, Butabarbital, Butalbital, Butorphanol, CarBAMazepine, Carbinoxamine, Cariprazine, Carisoprodol, Cetirizine (Systemic), Chloral Betaine, Chloral Hydrate, ChlordiazePOXIDE, Chlormethiazole, Chlorpheniramine, ChlorproMAZINE, Chlorzoxazone, Cinnarizine, Clemastine, CloBAZam, ClomiPRAMINE, ClonazePAM, CloNIDine, Clorazepate, Clothiapine, CloZAPine, Codeine, Cyclizine, Cyclobenzaprine, Cyproheptadine, Dantrolene, Desflurane, Desipramine, Desloratadine, Deutetrabenazine, Dexbrompheniramine, Dexchlorpheniramine, DiazePAM, Difenoxin, Dihydrocodeine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Diphenoxylate, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Efavirenz, Emedastine (Systemic), Entacapone, Eperisone, Estazolam, Eszopiclone, Ethosuximide, Ethotoin, Ethyl Loflazepate, Etizolam, Ezogabine, Felbamate, FentaNYL, Fexofenadine, Flibanserin, Flunarizine, Flunitrazepam, Flupentixol, FluPHENAZine, Flurazepam, Fosphenytoin, Gabapentin, Gabapentin Enacarbil, Glutethimide, GuanFACINE, Haloperidol, Halothane, Heroin, HYDROcodone, HYDROmorphone, HydrOXYzine, Iloperidone, Imipramine, Isoflurane, Ketamine, Ketotifen (Systemic), LamoTRIgine, LevETIRAcetam, Levocetirizine, Levorphanol, Lofepramine, Loprazolam, Loratadine, LORazepam, Lormetazepam, Loxapine, Lurasidone, Maprotiline, Meclizine, Melitracen [INT], Meperidine, Meprobamate, Meptazinol, Mequitazine, Metaxalone, Methadone, Methocarbamol, Methohexital, Methotrimeprazine, Methoxyflurane, Methsuximide, Mianserin, Midazolam, Mirtazapine, Molindone, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nalbuphine, Nalfurafine, Nefopam, Nitrazepam, Nitrous Oxide, Nordazepam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Opium, Opium Tincture, Orphenadrine, Oxatomide, Oxazepam, Oxomemazine, OxyCODONE, OxyMORphone, Paliperidone, Paraldehyde, Paregoric, Pentazocine, PENTobarbital, Perampanel, Periciazine, Perphenazine, Pheniramine, PHENobarbital, Phenyltoloxamine, Phenytoin, Pholcodine, Pimozide, Pipamperone [INT], Pipotiazine, Pizotifen, Pomalidomide, Prazepam, Pregabalin, Primidone, Prochlorperazine, Promazine, Promethazine, Propofol, Protriptyline, Pyrilamine (Systemic), Quazepam, QUEtiapine, Ramelteon, Remifentanil, Reserpine, Rilmenidine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Secobarbital, Sevoflurane, Sodium Oxybate, Stiripentol, SUFentanil, Sulpiride, Suvorexant, Tapentadol, Tasimelteon, Temazepam, Tetrabenazine, Thalidomide, Thiopental, Thioridazine, Thiothixene, Thonzylamine, TiaGABine, TiZANidine, Tofisopam, Tolcapone, Topiramate, TraMADol, Triazolam, Trifluoperazine, Trimeprazine, Trimipramine, Triprolidine, Valerian, Vigabatrin, Zaleplon, Ziconotide, Ziprasidone, Zolpidem, Zonisamide, Zopiclone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Hydroxyzine prescribing information cautions that hydroxyzine may potentiate the effects of other CNS depressant (e.g., narcotic analgesics, barbiturates, etc.) and recommends that the dose of other CNS depressants be reduced when used with hydroxyzine.<sup>1</sup><br><br>The mechanism for this interaction appears to be additive or synergistic CNS depressant effects with hydroxyzine, which is known to possess CNS depressant effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Vistaril (hydroxyzine). New York, NY: Pfizer Inc, April 2004.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5937":"<p><b>Title</b> Warfarin / RifAXIMin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> RifAXIMin may diminish the anticoagulant effect of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor clinical response to warfarin closely (e.g., INR, signs/symptoms of thrombosis) when used together with rifaximin, and particularly in patients who may have a gastrointestinal condition that may be associated with increased intestinal permeability.</p> \n<p><b>Discussion</b> A published report describes a patient who experienced a decrease in her INR following initiation of rifaximin for treatment of small intestinal bacterial overgrowth.<sup>1</sup> A substantial increase in the warfarin dose was required for the duration of rifaximin treatment (eventually leading to a temporary increase in INR), with a return to baseline warfarin dosing following cessation of rifaximin treatment.<br><br>The mechanism of this interaction is not clear, but the authors of the case report propose that the decrease in INR was at least partially due to rifaximin-mediated induction of CYP3A4, which is partially responsible for the metabolism of R-warfarin.<sup>1</sup> Though the extremely low rifaximin absorption/bioavailability generally limits any such enzyme inducing effects,<sup>2</sup> the drug has been shown to be capable of inducing CYP3A4,<sup>2</sup> and conditions such as small intestinal bacterial overgrowth have been associated with increased intestinal permeability,<sup>3</sup> potentially allowing sufficient rifaximin absorption for such an induction-related interaction to take place.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hoffman JT, Hartig C, Sonbol E, et al, “Probable Interaction Between Warfarin and Rifaximin in a Patient Treated for Small Intestine Bacterial Overgrowth,” <i>Ann Pharmacother</i>, 2011, Apr 19 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21505109\">[PubMed 21505109]</a>.</p>\n<p>2. Prescribing information. Xifaxin (rifaximin). Morrisville, NC: Salix Pharmaceuticals, Inc., Nov 2010.</p>\n<p>3. Husebye E, “The Pathogenesis of Gastrointestinal Bacterial Overgrowth,” <i>Chemotherapy</i>, 2005, 51 Suppl 1:1-22. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15855746\">[PubMed 15855746]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5938":"<p><b>Title</b> Vitamin D Analogs / Calcium Salts</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Calcium Salts may enhance the adverse/toxic effect of Vitamin D Analogs. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Patients receiving higher calcium doses together with a vitamin D analog should be followed closely for serum calcium (and phosphate, iPTH, etc., as appropriate) concentrations and for signs/symptoms of hypercalcemia.</p>\n<div>\n <p><b>Calcium Salts Interacting Members</b> Calcium Acetate, Calcium Carbonate, Calcium Chloride, Calcium Citrate, Calcium Glubionate, Calcium Gluconate, Calcium Lactate, Polycarbophil</p>\n <p><b>Vitamin D Analogs Interacting Members</b> Alfacalcidol, Calcifediol, Calcipotriene, Calcitriol (Systemic), Calcitriol (Topical), Cholecalciferol, Doxercalciferol, Ergocalciferol, Paricalcitol, Tacalcitol</p>\n</div> \n<p><b>Discussion</b> Concurrent use of high doses of calcium-containing products with a vitamin D analog may increase the risk for hypercalcemia. Patients receiving higher calcium doses together with a vitamin D analog should be followed closely for serum calcium (and phosphate, iPTH, etc., as appropriate) concentrations and for signs/symptoms of hypercalcemia. Though this specific warning is particularly included in the paricalcitol prescribing information,<sup>1</sup> the risk is common to all vitamin D analogs, which all warn of the potential for hypercalcemia that may be associated with their use.<br><br>Vitamin D is an important regulator of calcium absorption and handling, generally working to enhance serum calcium levels.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Zemplar (paricalcitol). North Chicago, IL: Abbott Laboratories, 3/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5939":"<p><b>Title</b> Linagliptin / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If such a combination must be used, monitor patients closely for evidence of reduced linagliptin effectiveness.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> According to study results cited in the linagliptin prescribing information, the average linagliptin AUC and maximum serum concentration (Cmax) were 40% and 44% lower, respectively, when rifampin (600 mg/day) and linagliptin (5 mg/day) were coadministered.<sup>1</sup><br><br>The specific mechanism of this interaction is unclear, with induction of CYP3A4-mediated metabolism and/or P-glycoprotein-mediated efflux of linagliptin the most likely mechanism. Of note, linagliptin is described as being primarily excreted as unchanged drug, with no substantial role for CYP3A4 metabolism noted.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Tradjenta (linagliptin). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., May 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5941":"<p><b>Title</b> Astemizole / Fosaprepitant</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Fosaprepitant may increase the serum concentration of Astemizole. The active metabolite aprepitant is likely responsible for this effect. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The combination of fosaprepitant and astemizole is listed as a contraindication in the fosaprepitant Canadian product monograph.</p> \n<p><b>Discussion</b> Fosaprepitant is a prodrug of aprepitant and is rapidly converted to aprepitant following administration.<sup>1</sup> Given the ability of aprepitant to inhibit the CYP3A4 enzyme responsible for the metabolism of astemizole, the fosaprepitant manufacturer states that fosaprepitant and astemizole should not be used in combination.<sup>1</sup> Aprepitant is a dose-dependent, moderate inhibitor of CYP3A4.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Emend IV (fosaprepitant). Kirkland QC, Canada: Merck Canada Inc., February 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5942":"<p><b>Title</b> Linagliptin / Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ritonavir may increase the serum concentration of Linagliptin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor clinical response to linagliptin closely when used with ritonavir. In particular, monitor for signs/symptoms of excessive response to linagliptin.</p> \n<p><b>Discussion</b> According to study results cited in the linagliptin prescribing information, the average linagliptin AUC and maximum serum concentration (Cmax) were approximately 2-fold and 3-fold higher, respectively, when ritonavir (200 mg twice/day) and linagliptin (5 mg x1) were coadministered.<sup>1</sup><br><br>The specific mechanism of this interaction is unclear, with inhibition of P-glycoprotein-mediated efflux of linagliptin a possible mechanism.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Tradjenta (linagliptin). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., May 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5943":"<p><b>Title</b> Simvastatin / Linagliptin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Linagliptin may increase the serum concentration of Simvastatin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The average simvastatin AUC and simvastatin acid AUC were each approximately 33% higher following 6 days of concurrent simvastatin (40 mg/day) and linagliptin (10 mg/day), versus simvastain alone, in a study of 20 healthy volunteers.<sup>1,2</sup><br><br>The specific mechanism of this interaction is unclear. According to both the study authors and the linagliptin prescribing information, this interaction is unlikely to be of clinical significance.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Graefe-Mody U, Huettner S, Stahle H, et al, “Effect of Linagliptin (BI 1356) on the Steady-State Pharmacokinetics of Simvastatin,” <i>Int J Clin Pharmacol Ther</i>, 2010, 48(6):367-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20497745\">[PubMed 20497745]</a></p>\n<p>2. Prescribing information. Tradjenta (linagliptin). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., May 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5944":"<p><b>Title</b> Terfenadine / Fosaprepitant</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Fosaprepitant may increase the serum concentration of Terfenadine. The active metabolite aprepitant is likely responsible for this effect. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The combination of fosaprepitant and terfenadine is listed as a contraindication in the fosaprepitant Canadian product monograph.</p> \n<p><b>Discussion</b> Fosaprepitant is a prodrug of aprepitant and is rapidly converted to aprepitant following administration.<sup>1</sup> Given the ability of aprepitant to inhibit the CYP3A4 enzyme responsible for the metabolism of terfenadine, the fosaprepitant manufacturer states that fosaprepitant and terfenadine should not be used in combination.<sup>1</sup> Aprepitant is a dose-dependent, moderate inhibitor of CYP3A4.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Emend IV (fosaprepitant). Kirkland QC, Canada: Merck Canada Inc., February 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5945":"<p><b>Title</b> Iloperidone / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 19 healthy volunteers, administration of ketoconazole (200 mg twice daily for 4 days) increased the AUC iloperidone (3 mg single oral dose) and its metabolites P88 and P95 by 57%, 55%, and 35%, respectively.<sup>1</sup> The likely primary mechanism of this interaction is ketoconazole inhibition of CYP3A4 mediated iloperidone metabolism. Iloperidone prescribing information recommends that iloperidone dose be reduced by half when administered with any strong CYP3A4 inhibitor.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Fanapt (iloperidone). Rockville, MD: Vanda Pharmaceuticals Inc., 3/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5946":"<p><b>Title</b> Iloperidone / CYP2D6 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P88 may be increased. CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P95 may be decreased. CYP2D6 Inhibitors (Strong) may increase the serum concentration of Iloperidone. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Reduce iloperidone dose by half when administered with a strong CYP2D6 inhibitor.</p>\n<div>\n <p><b>CYP2D6 Inhibitors (Strong) Interacting Members</b> FLUoxetine, PARoxetine, QuiNIDine, Tipranavir</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 23 healthy volunteers, administration of fluoxetine (20 mg twice daily for 21 days) increased the AUC of iloperidone (3 mg single oral dose) and its metabolite P88 by approximately 2-3 fold, and decreased the AUC of the metabolite P95 by roughly half.<sup>1</sup> Similarly, administration of paroxetine (20 mg daily for 5-8 days) in schizophrenic patients increased mean steady state concentrations of iloperidone (8 or 12 mg twice daily) and P88 by approximately 1.6 fold, while reducing concentrations of P95 by roughly half. The likely primary mechanism of these interactions is paroxetine/fluoxetine inhibition of CYP2D6 mediated iloperidone metabolism. Iloperidone prescribing information recommends that iloperidone dose be reduced by half when administered with any strong CYP2D6 inhibitor.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Fanapt (iloperidone). Rockville, MD: Vanda Pharmaceuticals Inc., 3/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5947":"<p><b>Title</b> Selective Serotonin Reuptake Inhibitors / CNS Depressants</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased psychomotor impairment in patients who initiate selective serotonin reuptake inhibitors during treatment with CNS depressants.</p>\n<div>\n <p><b>CNS Depressants Interacting Members</b> Acrivastine, Afloqualone, Alcohol (Ethyl), Alfentanil, ALPRAZolam, Amisulpride, Amitriptyline, Amobarbital, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Baclofen, Benperidol, Benzhydrocodone, Bilastine, Blonanserin, Brexpiprazole, Brimonidine (Ophthalmic), Brivaracetam, Bromazepam, Bromperidol, Brompheniramine, Buclizine, Buprenorphine, BusPIRone, Butabarbital, Butalbital, Butorphanol, CarBAMazepine, Carbinoxamine, Cariprazine, Carisoprodol, Cetirizine (Systemic), Chloral Betaine, Chloral Hydrate, ChlordiazePOXIDE, Chlormethiazole, Chlorpheniramine, ChlorproMAZINE, Chlorzoxazone, Cinnarizine, Clemastine, CloBAZam, ClomiPRAMINE, ClonazePAM, CloNIDine, Clorazepate, Clothiapine, CloZAPine, Codeine, Cyclizine, Cyclobenzaprine, Cyproheptadine, Dantrolene, Desflurane, Desipramine, Desloratadine, Deutetrabenazine, Dexbrompheniramine, Dexchlorpheniramine, DiazePAM, Difenoxin, Dihydrocodeine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Diphenoxylate, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Efavirenz, Emedastine (Systemic), Entacapone, Eperisone, Estazolam, Eszopiclone, Ethosuximide, Ethotoin, Ethyl Loflazepate, Etizolam, Ezogabine, Felbamate, FentaNYL, Fexofenadine, Flibanserin, Flunarizine, Flunitrazepam, Flupentixol, FluPHENAZine, Flurazepam, Fosphenytoin, Gabapentin, Gabapentin Enacarbil, Glutethimide, GuanFACINE, Haloperidol, Halothane, Heroin, HYDROcodone, HYDROmorphone, HydrOXYzine, Iloperidone, Imipramine, Isoflurane, Ketamine, Ketotifen (Systemic), LamoTRIgine, LevETIRAcetam, Levocetirizine, Levorphanol, Lofepramine, Loprazolam, Loratadine, LORazepam, Lormetazepam, Loxapine, Lurasidone, Maprotiline, Meclizine, Melitracen [INT], Meperidine, Meprobamate, Meptazinol, Mequitazine, Metaxalone, Methadone, Methocarbamol, Methohexital, Methotrimeprazine, Methoxyflurane, Methsuximide, Mianserin, Midazolam, Mirtazapine, Molindone, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nalbuphine, Nalfurafine, Nefopam, Nitrazepam, Nitrous Oxide, Nordazepam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Opium, Opium Tincture, Orphenadrine, Oxatomide, Oxazepam, Oxomemazine, OxyCODONE, OxyMORphone, Paliperidone, Paraldehyde, Paregoric, Pentazocine, PENTobarbital, Perampanel, Periciazine, Perphenazine, Pheniramine, PHENobarbital, Phenyltoloxamine, Phenytoin, Pholcodine, Pimozide, Pipamperone [INT], Pipotiazine, Pizotifen, Pomalidomide, Prazepam, Pregabalin, Primidone, Prochlorperazine, Promazine, Promethazine, Propofol, Protriptyline, Pyrilamine (Systemic), Quazepam, QUEtiapine, Ramelteon, Remifentanil, Reserpine, Rilmenidine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Secobarbital, Sevoflurane, Sodium Oxybate, Stiripentol, SUFentanil, Sulpiride, Suvorexant, Tapentadol, Tasimelteon, Temazepam, Tetrabenazine, Thalidomide, Thiopental, Thioridazine, Thiothixene, Thonzylamine, TiaGABine, TiZANidine, Tofisopam, Tolcapone, Topiramate, TraMADol, Triazolam, Trifluoperazine, Trimeprazine, Trimipramine, Triprolidine, Valerian, Vigabatrin, Zaleplon, Ziconotide, Ziprasidone, Zolpidem, Zonisamide, Zopiclone, Zuclopenthixol</p>\n <p><b>Selective Serotonin Reuptake Inhibitors Interacting Members</b> Citalopram, Dapoxetine, Escitalopram, FLUoxetine, FluvoxaMINE, PARoxetine, Sertraline, Vilazodone, Vortioxetine</p>\n</div> \n<p><b>Discussion</b> Manufacturers of selective serotonin reuptake inhibitors (SSRIs) describe a potential for impairment of cognitive and motor performance, and recommend that patients exercise caution operating potentially hazardous machinery and automobiles until reasonably sure that SSRI treatment does not affect their ability to engage in such activities.<sup>1,2,3,4,5,6,7</sup> While SSRIs are generally associated with a low potential to impair cognitive or motor performance, caution is advised when initiating therapy with SSRIs in patients receiving CNS depressants due to a possible elevated risk of such impairment.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Paxil (paroxetine). Research Triangle Park, NC: GlaxoSmithKline, March 2011.</p>\n<p>2. Prescribing information. Prozac (fluoxetine). Indianapolis, IN: Eli Lilly and Company, April 2011.</p>\n<p>3. Prescribing information. Zoloft (sertraline). New York, NY: Pfizer Inc, April 2011.</p>\n<p>4. Prescribing information. Celexa (citalopram). St. Louis, MO: Forest Pharmaceuticals, Inc., 1/2009.</p>\n<p>5. Prescribing information. Lexapro (escitalopram). St. Louis, MO: Forest Pharmaceuticals, Inc., 1/2009.</p>\n<p>6. Prescribing information. Luvox CR (fluvoxamine). Palo Alto, CA: Jazz Pharmaceuticals, Inc., 2/2009.</p>\n<p>7. Prescribing information. Viibryd (vilazodone). St. Louis, MO: Forest Pharmaceuticals, Inc., 4/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5948":"<p><b>Title</b> Selective Serotonin Reuptake Inhibitors / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Patients receiving selective serotonin reuptake inhibitors should be advised to avoid alcohol. Monitor for increased psychomotor impairment in patients who consume alcohol during treatment with selective serotonin reuptake inhibitors.</p>\n<div>\n <p><b>Selective Serotonin Reuptake Inhibitors Interacting Members</b> Citalopram, Dapoxetine, Escitalopram, FLUoxetine, FluvoxaMINE, PARoxetine, Sertraline, Vilazodone, Vortioxetine</p>\n</div> \n<p><b>Discussion</b> Manufacturers of selective serotonin reuptake inhibitors (SSRIs) advise that patients receiving these drugs should avoid alcohol.<sup>1,2,3,4,5,6,7</sup> SSRIs are generally associated with a low potential to impair cognitive or motor performance, and most manufacturers describe clinical studies in which combining SSRIs with alcohol had no impact on psychomotor impairment.<sup>1,3,4,5,6</sup> Nonetheless, caution is advised and patients who consume alcohol during treatment with SSRIs should be monitored for possible enhanced psychomotor impairment.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Paxil (paroxetine). Research Triangle Park, NC: GlaxoSmithKline, March 2011.</p>\n<p>2. Prescribing information. Prozac (fluoxetine). Indianapolis, IN: Eli Lilly and Company, April 2011.</p>\n<p>3. Prescribing information. Zoloft (sertraline). New York, NY: Pfizer Inc, April 2011.</p>\n<p>4. Prescribing information. Celexa (citalopram). St. Louis, MO: Forest Pharmaceuticals, Inc., 1/2009.</p>\n<p>5. Prescribing information. Lexapro (escitalopram). St. Louis, MO: Forest Pharmaceuticals, Inc., 1/2009.</p>\n<p>6. Prescribing information. Luvox CR (fluvoxamine). Palo Alto, CA: Jazz Pharmaceuticals, Inc., 2/2009.</p>\n<p>7. Prescribing information. Viibryd (vilazodone). St. Louis, MO: Forest Pharmaceuticals, Inc., 4/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5949":"<p><b>Title</b> BuPROPion / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the adverse/toxic effect of BuPROPion. Specifically, seizure threshold may be lowered. BuPROPion may enhance the adverse/toxic effect of Alcohol (Ethyl). Specifically, alcohol tolerance may decrease during treatment. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Patients receiving bupropion should be advised to minimize or avoid alcohol consumption due to possible lower alcohol tolerance, and lower seizure threshold associated with heavy alcohol consumption/abrupt discontinuation of heavy consumption.</p> \n<p><b>Discussion</b> Bupropion prescribing information advises that patients should minimize or avoid alcohol during treatment with bupropion due to a possible lower alcohol tolerance, and a reduced seizure threshold associated with heavy consumption or abrupt discontinuation.<sup>1</sup> Case reports have been published describing seizure and/or death associated with bupropion overdose in patients with elevated blood alcohol concentrations or a recent history of heavy alcohol consumption.<sup>2,3</sup><br><br>In a clinical study of 8 healthy volunteers, bupropion (100 mg single oral dose) and alcohol (40 g single oral dose) no impact on the pharmacokinetic properties of one another.<sup>3</sup> In a study of 12 healthy volunteers, bupropion (100 mg single oral dose) had no impact on measures of mental sedation, inebriation, reaction time, or short term memory following 16 or 32 g alcohol.<sup>4</sup> Auditory vigilance was significantly better with bupropion + 32 g alcohol compared to the alcohol alone.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Wellbutrin SR (bupropion). Research Triangle Park, NC: GlaxoSmithKline, May 2010.</p>\n<p>2. Ramcharitar V, Levine BS, Goldberger BA, et al, “Bupropion and Alcohol Fatal Intoxication: Case Report,” <i>Forensic Sci Int</i>, 1992, 56(2):151-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1452106\">[PubMed 1452106]</a></p>\n<p>3. Pesola GR and Avasarala J, “Bupropion Seizure Proportion Among New-Onset Generalized Seizures and Drug Related Seizures Presenting to an Emergency Department,” <i>J Emerg Med</i>, 2002, 22(3):235-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11932084\">[PubMed 11932084]</a></p>\n<p>3. Posner J, Bye A, Jeal S, et al, “Alcohol and Bupropion Pharmacokinetics in Healthy Male Volunteers,” <i>Eur J Clin Pharmacol</i>, 1984, 26(5):627-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6432553\">[PubMed 6432553]</a></p>\n<p>4. Hamilton MJ, Bush MS and Peck AW, “The Effect of Bupropion, a New Antidepressant Drug, and Alcohol and Their Interaction in Man,” <i>Eur J Clin Pharmacol</i>, 1984, 27(1):75-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6436033\">[PubMed 6436033]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5950":"<p><b>Title</b> Serotonin/Norepinephrine Reuptake Inhibitors / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the adverse/toxic effect of Serotonin/Norepinephrine Reuptake Inhibitors. Specifically, risks of psychomotor impairment may be enhanced. Alcohol (Ethyl) may enhance the hepatotoxic effect of Serotonin/Norepinephrine Reuptake Inhibitors. Particularly duloxetine and milnacipran. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Patients receiving serotonin/norepinephrine reuptake inhibitors (SNRIs) should be advised to avoid alcohol. Monitor for increased psychomotor impairment and hepatotoxicity in patients who consume alcohol during treatment with SNRIs.</p>\n<div>\n <p><b>Serotonin/Norepinephrine Reuptake Inhibitors Interacting Members</b> Desvenlafaxine, DULoxetine, Levomilnacipran, Milnacipran, Venlafaxine</p>\n</div> \n<p><b>Discussion</b> Manufacturers of serotonin/norepinephrine reuptake inhibitors (SNRIs) advise that patients receiving these drugs should avoid alcohol.<sup>1,2,3,4</sup> SNRIs are generally associated with a low potential to impair cognitive or motor performance, and most manufacturers describe clinical studies in which combining SNRIs with alcohol had no impact on psychomotor impairment.<sup>1,3,4</sup> Nonetheless, caution is advised and patients who consume alcohol during treatment with SNRIs should be monitored for possible enhanced psychomotor impairment. The manufacturers of duloxetine and milnacipran warn additionally that hepatotoxic effects of these drugs may be enhanced by alcohol consumption.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Cymbalta (duloxetine). Indianapolis, IN: Eli Lilly and Company, 3/2010.</p>\n<p>2. Prescribing information. Savella (milnacipran). St. Louis, MO: Forest Pharmaceuticals, Inc., 1/2009.</p>\n<p>3. Prescribing information. Effexor (venlafaxine). Philadelphia, PA: Wyeth Pharmaceuticals Inc., 7/2009.</p>\n<p>4. Prescribing information. Pristiq (desvenlafaxine). Philadelphia, PA: Wyeth Pharmaceuticals Inc., 2/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5951":"<p><b>Title</b> NIFEdipine / FLUoxetine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> FLUoxetine may enhance the adverse/toxic effect of NIFEdipine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased nifedipine effects in patients receiving fluoxetine.</p> \n<p><b>Discussion</b> Two case reports describe patients who developed symptoms consistent with nifedipine adverse effects (tachycardia, orthostatic hypotension, weakness, nausea, flushing) following initiation of fluoxetine.<sup>1,2</sup> Symptoms abated in one case following a reduction of the nifedipine dose by half, and in the other following discontinuation of fluoxetine.<br><br>The mechanism of this possible interaction is unknown. The manufacturer of one nifedipine product warns that fluoxetine may increase nifedipine exposure via inhibition of CYP3A mediated metabolism.<sup>3</sup> However, the absence of pharmacokinetic interactions between fluoxetine and midazolam or triazolam strongly suggests that fluoxetine inhibition of CYP3A is at best weak (and therefore unlikely to be clinically consequential in most patients).<sup>4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Azaz-Livshits TL and Danenberg HD, “Tachycardia, Orthostatic Hypotension and Profound Weakness due to Concomitant Use of Fluoxetine and Nifedipine,” <i>Pharmacopsychiatry</i>, 1997, 30(6):274-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9442553\">[PubMed 9442553]</a></p>\n<p>2. Sternbach H, “Fluoxetine-Associated Potentiation of Calcium-Channel Blockers,” <i>J Clin Psychopharmacol</i>, 1991, 11(6):390-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1770159\">[PubMed 1770159]</a></p>\n<p>3. Prescribing information. Adalat CC (nifedipine). Whitehouse Station, NJ: Merck &amp; Co., Inc., August 2010.</p>\n<p>4. Lam YW, Alfaro CL, Ereshefsky L, et al, “Pharmacokinetic and Pharmacodynamic Interactions of Oral Midazolam With Ketoconazole, Fluoxetine, Fluvoxamine, and Nefazodone,” <i>J Clin Pharmacol</i>, 2003, 43(11):1274-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14551182\">[PubMed 14551182]</a></p>\n<p>5. Wright CE, Lasher-Sisson TA, Steenwyk RC, et al, “A Pharmacokinetic Evaluation of the Combined Administration of Triazolam and Fluoxetine,” <i>Pharmacotherapy</i>, 1992, 12(2):103-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1570226\">[PubMed 1570226]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5952":"<p><b>Title</b> Octreotide / Everolimus</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Everolimus may increase the serum concentration of Octreotide. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of patients with neuroendocrine tumors, 150 patients who received everolimus (10 mg daily) and long-acting octreotide (30 mg every 28 days) had octreotide trough concentrations that were 47% higher than those of the 144 patients who received long-acting octreotide alone.<sup>1</sup> Octreotide trough concentrations did not correlate with clinical efficacy, suggesting the clinical benefits of the combination are pharmacodynamic in nature and the observed pharmacokinetic interaction is likely of little clinical significance. <br><br>The mechanism of this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Pavel ME, Becerra C, Grosch K, Cheung W, Hasskarl J, Yao JC. Effect of everolimus on the pharmacokinetics of octreotide long-acting repeatable in patients with advanced neuroendocrine tumors: an analysis of the randomized phase III RADIANT-2 trial. <i>Clin Pharmacol Ther</i>. 2017;101(4):462-468. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28032910\">[PubMed 28032910]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5953":"<p><b>Title</b> Raltegravir / Fosamprenavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fosamprenavir may decrease the serum concentration of Raltegravir. Raltegravir may decrease the serum concentration of Fosamprenavir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider alternatives to combined treatment with raltegravir and fosamprenavir, as appropriate doses of these drugs has not been established with their combined use.</p> \n<p><b>Discussion</b> Fosamprenavir prescribing information describes several studies of the pharmacokinetic impact of raltegravir coadministration with fosamprenavir.<sup>1</sup> All used a raltegravir dose of 400 mg twice daily for 14 days and contained 12-14 subjects (stars below denote “significant” values where 90% confidence intervals do not overlap 0). Coadministration of raltegravir decreased amprenavir maximum concentration (Cmax), minimum concentration (Cmin), and AUC from fosamprenavir (1,400 mg twice daily) by 15%* (27% with fasting), 32%* (43%* with fasting), and 17%* (36%* with fasting), respectively. Coadministration of raltegravir decreased amprenavir Cmax, Cmin, and AUC from fosamprenavir/ritonavir (700/100 mg twice daily) by 25% (14%* with fasting), 33%* (20% with fasting), and 25% (17% with fasting), respectively. Coadministration of raltegravir decreased non-fasting amprenavir Cmax, Cmin, and AUC from fosamprenavir/ritonavir (1,400/100 mg twice daily) by 18%, 50%* and 24%, respectively, while fasting Cmax increased by 27%, Cmin decreased by 17%, and AUC increased by 13%. The manufacturer also indicates that fosamprenavir may decrease concentrations of raltegravir, although no data are given. The mechanisms of these interactions are unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Lexiva (fosamprenavir). Research Triangle Park, NC: ViiV Healthcare, May 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5954":"<p><b>Title</b> Sodium Phosphates / Angiotensin-Converting Enzyme Inhibitors</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: This interaction has only been demonstrated with large oral sodium phosphate doses used for bowel preparation (typically greater than 20 g).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Angiotensin-Converting Enzyme Inhibitors may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider avoiding this combination by temporarily suspending treatment with angiotensin-converting enzyme inhibitors, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril, Cilazapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Zofenopril</p>\n</div> \n<p><b>Discussion</b> Several case reports and series describe development of acute phosphate nephropathy (APhN) in patients receiving angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) at the time of oral sodium phosphate bowel preparation.<sup>1,2,3,4,5,6,7,8,9,10</sup> Additionally, several retrospective reviews have implicated treatment with ACE inhibitors and/or ARBs as a risk factor for development of APhN.<sup>11,12,13,14,15</sup> Sodium phosphate prescribing information includes a warning about this increased risk, and lists hypovolemia, baseline kidney disease, increased age, treatment with diuretics, and treatment with nonsteroidal anti-inflammatory drugs as other possible risk factors for development of APhN.<sup>16</sup> <br><br>The mechanism of this interaction has not been investigated. Several factors may predispose patients treated with ACE inhibitors and ARBs to tubular calcium phosphate precipitation/deposition and renal injury, including decreased renal perfusion (predisposing to prerenal states and phosphate retention), impaired vascular response to hypovolemia due to underlying hypertension, and possibly decreased angiotensin II dependent proximal tubular bicarbonate resorption.<sup>17</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Demoulin N, Jadoul M, Cosyns JP, et al, “An Easily Overlooked Iatrogenic Cause of Renal Failure,” <i>Clin Nephrol</i>, 2008, 70(2):176-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18793536\">[PubMed 18793536]</a></p>\n<p>2. Aasebo W, Scott H and Ganss R, “Kidney Biopsies Taken Before and After Oral Sodium Phosphate Bowel Cleansing,” <i>Nephrol Dial Transplant</i>, 2007, 22(3):920-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17138571\">[PubMed 17138571]</a></p>\n<p>3. Rocuts AK, Waikar SS, Alexander MP, et al, “Acute Phosphate Nephropathy,” <i>Kidney Int</i>, 2009, 75(9):987-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18580858\">[PubMed 18580858]</a></p>\n<p>4. Slee TM, Vleming LJ and Valentijn RM, “Renal Failure Due to Acute Phosphate Nephropathy,” <i>Neth J Med</i>, 2008, 66(10):438-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19011271\">[PubMed 19011271]</a></p>\n<p>5. Manley P, Somerfield J, Simpson I, et al, “Bilateral Uraemic Optic Neuritis Complicating Acute Nephrocalcinosis,” <i>Nephrol Dial Transplant</i>, 2006, 21(10):2957-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16782990\">[PubMed 16782990]</a></p>\n<p>6. Markowitz GS, Stokes MB, Radhakrishnan J, et al, “Acute Phosphate Nephropathy Following Oral Sodium Phosphate Bowel Purgative: An Underrecognized Cause of Chronic Renal Failure,” <i>J Am Soc Nephrol</i>, 2005, 16(11):3389-96. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16192415\">[PubMed 16192415]</a></p>\n<p>7. Ori Y, Herman M, Tobar A, et al, “Acute Phosphate Nephropathy-An Emerging Threat,” <i>Am J Med Sci</i>, 2008, 336(4):309-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18854672\">[PubMed 18854672]</a></p>\n<p>8. Santos P, Branco A, Silva S, et al, “Acute Phosphate Nephropathy After Bowel Cleansing: Still a Menace,” <i>Nefrologia</i>, 2010, 30(6):702-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21113224\">[PubMed 21113224]</a></p>\n<p>9. Palmadottir VK, Gudmundsson H, Hardarson S, et al, “Incidence and Outcome of Acute Phosphate Nephropathy in Iceland,” <i>PLoS One</i>, 2010, 5(10):e13484. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20976065\">[PubMed 20976065]</a></p>\n<p>10. Mackey AC, Green L, Amand KS, et al, “Sodium Phosphate Tablets and Acute Phosphate Nephropathy,” <i>Am J Gastroenterol</i>, 2009, 104(8):1903-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19661931\">[PubMed 19661931]</a></p>\n<p>11. Singal AK, Rosman AS, Post JB, et al, “The Renal Safety of Bowel Preparations for Colonoscopy: A Comparative Study of Oral Sodium Phosphate Solution and Polyethylene Glycol,” <i>Aliment Pharmacol Ther</i>, 2008, 27(1):41-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17956596\">[PubMed 17956596]</a></p>\n<p>12. Russmann S, Lamerato L, Marfatia A, et al, “Risk of Impaired Renal Function After Colonoscopy: A Cohort Study in Patients Receiving Either Oral Sodium Phosphate or Polyethylene Glycol,” <i>Am J Gastroenterol</i>, 2007, 102(12):2655-63. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17970832\">[PubMed 17970832]</a></p>\n<p>13. Brunelli SM, Lewis JD, Gupta M, et al, “Risk of Kidney Injury Following Oral Phosphosoda Bowel Preparations,” <i>J Am Soc Nephrol</i>, 2007, 18(12):3199-205. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17978309\">[PubMed 17978309]</a></p>\n<p>14. Hurst FP, Bohen EM, Osgard EM, et al, “Association of Oral Sodium Phosphate Purgative Use With Acute Kidney Injury,” <i>J Am Soc Nephrol</i>, 2007, 18(12):3192-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17978311\">[PubMed 17978311]</a></p>\n<p>15. Khurana A, McLean L, Atkinson S, et al, “The Effect of Oral Sodium Phosphate Drug Products on Renal Function in Adults Undergoing Bowel Endoscopy,” <i>Arch Intern Med</i>, 2008, 168(6):593-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18362251\">[PubMed 18362251]</a></p>\n<p>16. Prescribing information. Osmoprep (sodium phosphate, monobasic, monohydrate, sodium phosphate, dibasic anhydrous). Morrisville, NC: Salix Pharmaceuticals, Inc, March 2009.</p>\n<p>17. Markowitz GS and Perazella MA, “Acute Phosphate Nephropathy,” <i>Kidney Int</i>, 2009, 76(10):1027-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19675530\">[PubMed 19675530]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5955":"<p><b>Title</b> Sodium Phosphates / Angiotensin II Receptor Blockers</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: This interaction has only been demonstrated with large oral sodium phosphate doses used for bowel preparation (typically greater than 20 g).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Angiotensin II Receptor Blockers may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider avoiding this combination by temporarily suspending treatment with angiotensin II receptor blockers, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.</p>\n<div>\n <p><b>Angiotensin II Receptor Blockers Interacting Members</b> Azilsartan, Candesartan, Eprosartan, Fimasartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan</p>\n</div> \n<p><b>Discussion</b> Several case reports and series describe development of acute phosphate nephropathy (APhN) in patients receiving angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) at the time of oral sodium phosphate bowel preparation.<sup>1,2,3,4,5,6,7,8,9,10</sup> Additionally, several retrospective reviews have implicated treatment with ACE inhibitors and/or ARBs as a risk factor for development of APhN.<sup>11,12,13,14,15</sup> Sodium phosphate prescribing information includes a warning about this increased risk, and lists hypovolemia, baseline kidney disease, increased age, treatment with diuretics, and treatment with nonsteroidal anti-inflammatory drugs as other possible risk factors for development of APhN.<sup>16</sup> <br><br>The mechanism of this interaction has not been investigated. Several factors may predispose patients treated with ACE inhibitors and ARBs to tubular calcium phosphate precipitation/deposition and renal injury, including decreased renal perfusion (predisposing to prerenal states and phosphate retention), impaired vascular response to hypovolemia due to underlying hypertension, and possibly decreased angiotensin II dependent proximal tubular bicarbonate resorption.<sup>17</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Demoulin N, Jadoul M, Cosyns JP, et al, “An Easily Overlooked Iatrogenic Cause of Renal Failure,” <i>Clin Nephrol</i>, 2008, 70(2):176-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18793536\">[PubMed 18793536]</a></p>\n<p>2. Aasebo W, Scott H and Ganss R, “Kidney Biopsies Taken Before and After Oral Sodium Phosphate Bowel Cleansing,” <i>Nephrol Dial Transplant</i>, 2007, 22(3):920-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17138571\">[PubMed 17138571]</a></p>\n<p>3. Rocuts AK, Waikar SS, Alexander MP, et al, “Acute Phosphate Nephropathy,” <i>Kidney Int</i>, 2009, 75(9):987-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18580858\">[PubMed 18580858]</a></p>\n<p>4. Slee TM, Vleming LJ and Valentijn RM, “Renal Failure Due to Acute Phosphate Nephropathy,” <i>Neth J Med</i>, 2008, 66(10):438-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19011271\">[PubMed 19011271]</a></p>\n<p>5. Manley P, Somerfield J, Simpson I, et al, “Bilateral Uraemic Optic Neuritis Complicating Acute Nephrocalcinosis,” <i>Nephrol Dial Transplant</i>, 2006, 21(10):2957-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16782990\">[PubMed 16782990]</a></p>\n<p>6. Markowitz GS, Stokes MB, Radhakrishnan J, et al, “Acute Phosphate Nephropathy Following Oral Sodium Phosphate Bowel Purgative: An Underrecognized Cause of Chronic Renal Failure,” <i>J Am Soc Nephrol</i>, 2005, 16(11):3389-96. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16192415\">[PubMed 16192415]</a></p>\n<p>7. Ori Y, Herman M, Tobar A, et al, “Acute Phosphate Nephropathy-An Emerging Threat,” <i>Am J Med Sci</i>, 2008, 336(4):309-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18854672\">[PubMed 18854672]</a></p>\n<p>8. Santos P, Branco A, Silva S, et al, “Acute Phosphate Nephropathy After Bowel Cleansing: Still a Menace,” <i>Nefrologia</i>, 2010, 30(6):702-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21113224\">[PubMed 21113224]</a></p>\n<p>9. Palmadottir VK, Gudmundsson H, Hardarson S, et al, “Incidence and Outcome of Acute Phosphate Nephropathy in Iceland,” <i>PLoS One</i>, 2010, 5(10):e13484. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20976065\">[PubMed 20976065]</a></p>\n<p>10. Mackey AC, Green L, Amand KS, et al, “Sodium Phosphate Tablets and Acute Phosphate Nephropathy,” <i>Am J Gastroenterol</i>, 2009, 104(8):1903-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19661931\">[PubMed 19661931]</a></p>\n<p>11. Singal AK, Rosman AS, Post JB, et al, “The Renal Safety of Bowel Preparations for Colonoscopy: A Comparative Study of Oral Sodium Phosphate Solution and Polyethylene Glycol,” <i>Aliment Pharmacol Ther</i>, 2008, 27(1):41-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17956596\">[PubMed 17956596]</a></p>\n<p>12. Russmann S, Lamerato L, Marfatia A, et al, “Risk of Impaired Renal Function After Colonoscopy: A Cohort Study in Patients Receiving Either Oral Sodium Phosphate or Polyethylene Glycol,” <i>Am J Gastroenterol</i>, 2007, 102(12):2655-63. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17970832\">[PubMed 17970832]</a></p>\n<p>13. Brunelli SM, Lewis JD, Gupta M, et al, “Risk of Kidney Injury Following Oral Phosphosoda Bowel Preparations,” <i>J Am Soc Nephrol</i>, 2007, 18(12):3199-205. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17978309\">[PubMed 17978309]</a></p>\n<p>14. Hurst FP, Bohen EM, Osgard EM, et al, “Association of Oral Sodium Phosphate Purgative Use With Acute Kidney Injury,” <i>J Am Soc Nephrol</i>, 2007, 18(12):3192-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17978311\">[PubMed 17978311]</a></p>\n<p>15. Khurana A, McLean L, Atkinson S, et al, “The Effect of Oral Sodium Phosphate Drug Products on Renal Function in Adults Undergoing Bowel Endoscopy,” <i>Arch Intern Med</i>, 2008, 168(6):593-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18362251\">[PubMed 18362251]</a></p>\n<p>16. Prescribing information. Osmoprep (sodium phosphate, monobasic, monohydrate, sodium phosphate, dibasic anhydrous). Morrisville, NC: Salix Pharmaceuticals, Inc, March 2009.</p>\n<p>17. Markowitz GS and Perazella MA, “Acute Phosphate Nephropathy,” <i>Kidney Int</i>, 2009, 76(10):1027-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19675530\">[PubMed 19675530]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5956":"<p><b>Title</b> Nonsteroidal Anti-Inflammatory Agents / Sodium Phosphates</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: This interaction has only been demonstrated with large oral sodium phosphate doses used for bowel preparation (typically greater than 20 g).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Sodium Phosphates may enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider avoiding this combination by temporarily suspending treatment with nonsteroidal anti-inflammatory drugs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> Several case reports describe development of acute phosphate nephropathy (APhN) in patients receiving nonsteroidal anti-inflammatory agents (NSAIDs) at the time of oral sodium phosphate bowel preparation.<sup>1,2,3</sup> Additionally, one retrospective review identified treatment with NSAIDs as a risk factor for development of APhN.<sup>4</sup> Sodium phosphate prescribing information includes a warning about this increased risk, and lists hypovolemia, baseline kidney disease, increased age, and treatment with angiotensin converting enzyme inhibitors or angiotensin II receptor blockers as other possible risk factors for development of APhN.<sup>5</sup><br><br>The mechanism of this possible interaction has not been investigated. Treatment with NSAIDs has been associated with decreased renal perfusion and a number of different forms of renal injury, all of which could predispose to calcium phosphate precipitation/deposition either directly or indirectly.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Markowitz GS, Stokes MB, Radhakrishnan J, et al, “Acute Phosphate Nephropathy Following Oral Sodium Phosphate Bowel Purgative: An Underrecognized Cause of Chronic Renal Failure,” <i>J Am Soc Nephrol</i>, 2005, 16(11):3389-96. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16192415\">[PubMed 16192415]</a></p>\n<p>2. Rocuts AK, Waikar SS, Alexander MP, et al, “Acute Phosphate Nephropathy,” <i>Kidney Int</i>, 2009, 75(9):987-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18580858\">[PubMed 18580858]</a></p>\n<p>3. Mackey AC, Green L, Amand KS, et al, “Sodium Phosphate Tablets and Acute Phosphate Nephropathy,” <i>Am J Gastroenterol</i>, 2009, 104(8):1903-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19661931\">[PubMed 19661931]</a></p>\n<p>4. Singal AK, Rosman AS, Post JB, et al, “The Renal Safety of Bowel Preparations for Colonoscopy: A Comparative Study of Oral Sodium Phosphate Solution and Polyethylene Glycol,” <i>Aliment Pharmacol Ther</i>, 2008, 27(1):41-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17956596\">[PubMed 17956596]</a></p>\n<p>5. Prescribing information. Osmoprep (sodium phosphate, monobasic, monohydrate, sodium phosphate, dibasic anhydrous). Morrisville, NC: Salix Pharmaceuticals, Inc, March 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5957":"<p><b>Title</b> Sodium Phosphates / Diuretics</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: This interaction has only been demonstrated with large oral sodium phosphate doses used for bowel preparation (typically greater than 20 g).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor fluid/electrolyte and renal status closely.</p>\n<div>\n <p><b>Diuretics Interacting Members</b> AcetaZOLAMIDE, AMILoride, Bendroflumethiazide, Bumetanide, Chlorothiazide, Chlorthalidone, Cyclopenthiazide, Dichlorphenamide, Eplerenone, Ethacrynic Acid, Furosemide, HydroCHLOROthiazide, Hydroflumethiazide, Indapamide, Isosorbide Solution (Diuretic), Mannitol (Systemic), MethazolAMIDE, Methyclothiazide, MetOLazone, Spironolactone, Torsemide, Triamterene, Xipamide</p>\n</div> \n<p><b>Discussion</b> Several case reports describe development of acute phosphate nephropathy (APhN) in patients receiving diuretics at the time of oral sodium phosphate bowel preparation.<sup>1,2,3,4,5,6</sup> Additionally, four retrospective reviews identified treatment with diuretics as a risk factor for development of APhN.<sup>7,8,9,10</sup> Sodium phosphate prescribing information includes a warning about this increased risk, and lists hypovolemia, baseline kidney disease, increased age, treatment with nonsteroidal anti-inflammatory drugs, and treatment with angiotensin converting enzyme inhibitors or angiotensin II receptor blockers as other possible risk factors for development of APhN.<sup>11</sup> Diuretic classes specifically implicated in the cited reports include thiazide and loop diuretics, although the warning in sodium phosphate prescribing information is applied to diuretics in general.<br><br>The mechanism of this interaction has not been investigated. Treatment with diuretics may contribute to the risk of acute phosphate nephropathy via volume depletion, alterations in renal electrolyte handling, or exacerbation of pre-renal states (potentially predisposing patients to phosphate retention and calcium phosphate precipitation/deposition).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Aasebo W, Scott H and Ganss R, “Kidney Biopsies Taken Before and After Oral Sodium Phosphate Bowel Cleansing,” <i>Nephrol Dial Transplant</i>, 2007, 22(3):920-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17138571\">[PubMed 17138571]</a></p>\n<p>2. Rocuts AK, Waikar SS, Alexander MP, et al, “Acute Phosphate Nephropathy,” <i>Kidney Int</i>, 2009, 75(9):987-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18580858\">[PubMed 18580858]</a></p>\n<p>3. Slee TM, Vleming LJ and Valentijn RM, “Renal Failure Due to Acute Phosphate Nephropathy,” <i>Neth J Med</i>, 2008, 66(10):438-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19011271\">[PubMed 19011271]</a></p>\n<p>4. Manley P, Somerfield J, Simpson I, et al, “Bilateral Uraemic Optic Neuritis Complicating Acute Nephrocalcinosis,” <i>Nephrol Dial Transplant</i>, 2006, 21(10):2957-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16782990\">[PubMed 16782990]</a></p>\n<p>5. Markowitz GS, Stokes MB, Radhakrishnan J, et al, “Acute Phosphate Nephropathy Following Oral Sodium Phosphate Bowel Purgative: An Underrecognized Cause of Chronic Renal Failure,” <i>J Am Soc Nephrol</i>, 2005, 16(11):3389-96. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16192415\">[PubMed 16192415]</a></p>\n<p>6. Palmadottir VK, Gudmundsson H, Hardarson S, et al, “Incidence and Outcome of Acute Phosphate Nephropathy in Iceland,” <i>PLoS One</i>, 2010, 5(10):e13484. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20976065\">[PubMed 20976065]</a></p>\n<p>7. Singal AK, Rosman AS, Post JB, et al, “The Renal Safety of Bowel Preparations for Colonoscopy: A Comparative Study of Oral Sodium Phosphate Solution and Polyethylene Glycol,” <i>Aliment Pharmacol Ther</i>, 2008, 27(1):41-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17956596\">[PubMed 17956596]</a></p>\n<p>8. Russmann S, Lamerato L, Marfatia A, et al, “Risk of Impaired Renal Function After Colonoscopy: A Cohort Study in Patients Receiving Either Oral Sodium Phosphate or Polyethylene Glycol,” <i>Am J Gastroenterol</i>, 2007, 102(12):2655-63. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17970832\">[PubMed 17970832]</a></p>\n<p>9. Brunelli SM, Lewis JD, Gupta M, et al, “Risk of Kidney Injury Following Oral Phosphosoda Bowel Preparations,” <i>J Am Soc Nephrol</i>, 2007, 18(12):3199-205. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17978309\">[PubMed 17978309]</a></p>\n<p>10. Hurst FP, Bohen EM, Osgard EM, et al, “Association of Oral Sodium Phosphate Purgative Use With Acute Kidney Injury,” <i>J Am Soc Nephrol</i>, 2007, 18(12):3192-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17978311\">[PubMed 17978311]</a></p>\n<p>11. Prescribing information. Osmoprep (sodium phosphate, monobasic, monohydrate, sodium phosphate, dibasic anhydrous). Morrisville, NC: Salix Pharmaceuticals, Inc, March 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5958":"<p><b>Title</b> Sodium Phosphates / Tricyclic Antidepressants</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: Warnings about this interaction appear only in prescribing information for oral sodium phosphate products used in large doses (typically greater than 20 g) for bowel preparation.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Tricyclic Antidepressants may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure and/or loss of consciousness may be increased in patients with significant sodium phosphate induced fluid/electrolyte abnormalities. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Closely monitor fluid/electrolyte status, correcting as needed, to limit the risk of neurologic abnormalities (seizure, loss of consciousness) in patients who receive sodium phosphate bowel preparation during treatment with tricyclic antidepressants.</p>\n<div>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline, Amoxapine, ClomiPRAMINE, Desipramine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine, Lofepramine, Melitracen [INT], Nortriptyline, Protriptyline, Trimipramine</p>\n</div> \n<p><b>Discussion</b> According to sodium phosphate prescribing information, tricyclic antidepressant use may predispose patients to seizure and loss of consciousness when administered in the setting of fluid and electrolyte abnormalities induced by sodium phosphate bowel preparation.<sup>1</sup> Therefore, close monitoring of fluid/electrolyte status and correction of significant abnormalities may be of particular importance in TCA treated patients.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Osmoprep (sodium phosphate, monobasic, monohydrate, sodium phosphate, dibasic anhydrous). Morrisville, NC: Salix Pharmaceuticals, Inc, March 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5959":"<p><b>Title</b> Opioid Analgesics / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Cimetidine may enhance the analgesic effect of Opioid Analgesics. Cimetidine may enhance the respiratory depressant effect of Opioid Analgesics. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> No action required. Despite one case report describing a possible clinically significant interaction, studies have questioned the clinical significance of this potential interaction.</p>\n<div>\n <p><b>Opioid Analgesics Interacting Members</b> Alfentanil, Benzhydrocodone, Buprenorphine, Butorphanol, Codeine, Dihydrocodeine, FentaNYL, Heroin, HYDROcodone, HYDROmorphone, Levorphanol, Meperidine, Meptazinol, Methadone, Morphine (Liposomal), Morphine (Systemic), Nalbuphine, Opium, Opium Tincture, OxyCODONE, OxyMORphone, Paregoric, Pentazocine, Remifentanil, SUFentanil, Tapentadol, TraMADol</p>\n</div> \n<p><b>Discussion</b> A published report describes a patient who experienced severe respiratory depression, confusion, disorientation, and muscle twitching on two separate occasions following concurrent use of cimetidine (300 mg TID during first occurrence, and 150 mg BID during second occurrence) and an opioid analgesic (morphine 15 mg intramuscular every 4 hours at first occurrence, and Pantopon (mixture of all opium alkaloids, roughly equivalent potency to morphine) 15 mg intramuscular every 3-6 hours at the second occurrence).<sup>1</sup> Of note, the patient had been treated with morphine at roughly similar doses (but without concurrent cimetidine) within a few months prior to the first occurrence of this response with no such evidence of toxicity. The authors of this report attribute the patient's reactions to an interaction between cimetidine and the opioid analgesic. The prescribing information for at least one opioid recommends caution with concurrent cimetidine due to the potential for increased CNS side effects.<sup>2</sup><br><br>Several animal studies have similarly reported enhanced opioid analgesia with concurrent cimetidine.<sup>3,4,5</sup> A small study of healthy volunteers also reported that cimetidine prolonged morphine-associated respiratory depression, but concluded that the effect was small and unlikely to be of clinical significance.<sup>6</sup><br><br>The magnitude for such a possible interaction is uncertain. Despite one study in rats that found increased CNS morphine concentrations with cimetidine,<sup>3</sup> a study in 7 healthy volunteers found that cimetidine administration was not associated with any changes in morphine clearance, volume of distribution, AUC, or half-life.<sup>7</sup> In contrast to these findings with morphine, clinical and animal data do suggest a possible pharmacokinetic interaction between cimetidine and meperidine and methadone,<sup>8,9,10</sup> but these likely represent findings unique to these specific opioids.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Fine A, Churchill DN, “Potentially Lethal Interaction of Cimetidine and Morphine,” <i>Can Med Assoc J</i>, 1981, 124(11):1434-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7237324\">[PubMed 7237324]</a></p>\n<p>2. Prescribing information. Opana (oxymorphone). Hazelwood, MO: Mallinckrodt Brand Pharmaceuticals, Inc., 03/2010.</p>\n<p>3. Gogas KR, Hough LB, Eberle NB, et al, “A Role for Histamine and H2-Receptors in Opioid Antinociception,” <i>J Pharmacol Exp Ther</i>, 1989, 250(2):476-84. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2547933\">[PubMed 2547933]</a></p>\n<p>4. Bluhm R, Zsigmond EK, Winnie AP, “Potentiation of Opioid Analgesia by H1 and H2 Antagonists,” <i>Life Sci</i>, 1982, 31(12-13):1229-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6128651\">[PubMed 6128651]</a></p>\n<p>5. Robertson JA, Hough LB, Bodnar RJ, “Potentiation of Opioid and Nonopioid Forms of Swim Analgesia by Cimetidine,” <i>Pharmacol Biochem Behav</i>, 1988, 31(1):107-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2855266\">[PubMed 2855266]</a></p>\n<p>6. Lam AM, Clement JL, “Effect of Cimetidine Premedication on Morphine-Induced Ventilatory Depression,” <i>Can Anaesth Soc J</i>, 1984, 31(1):36-43. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6420025\">[PubMed 6420025]</a></p>\n<p>7. Mojaverian P, Fedder IL, Vlasses PH, et al, “Cimetidine Does Not Alter Morphine Disposition in Man,” <i>Br J Clin Pharmacol</i>, 1982, 14(6):809-13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7150459\">[PubMed 7150459]</a></p>\n<p>8. Dawson GW, Vestal RE, “Cimetidine Inhibits the In Vitro N-Demethylation of Methadone,” <i>Res Commun Chem Pathol Pharmacol</i>, 1984, 46(2):301-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6515123\">[PubMed 6515123]</a></p>\n<p>9. Guay DR, Meatherall RC, Chalmers JL, et al, “Cimetidine Alters Pethidine Disposition in Man,” <i>Br J Clin Pharmacol</i>, 1984, 18(6):907-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6529532\">[PubMed 6529532]</a></p>\n<p>10. Eisendrath SJ, Goldman B, Douglas J, et al, “Meperidine-Induced Delirium,” <i>Am J Psychiatry</i>, 1987, 144(8):1062-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3605428\">[PubMed 3605428]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5960":"<p><b>Title</b> Pentoxifylline / Ketorolac (Nasal)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ketorolac (Nasal) may enhance the adverse/toxic effect of Pentoxifylline. Specifically, the risk of bleeding may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of nasal ketorolac with pentoxifylline is contraindicated due to an increased risk of bleeding.</p> \n<p><b>Discussion</b> Nasal ketorolac prescribing information lists concomitant use with pentoxifylline as contraindicated, due to an increased tendency for bleeding.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Sprix (ketorolac). Shirley, NY: American Regent, Inc., 1/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5961":"<p><b>Title</b> Ketorolac (Nasal) / Probenecid</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Probenecid may increase the serum concentration of Ketorolac (Nasal). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of nasal ketorolac with probenecid is contraindicated due to an increased risk of ketorolac adverse effects (due to significant increase in ketorolac exposure with the combination).</p> \n<p><b>Discussion</b> Per nasal ketorolac prescribing information, use of ketorolac with probenecid has been associated with significant decreases in ketorolac clearance and volume of distribution, a 3-fold increase in ketorolac AUC, and more than a 2-fold increase in ketorolac elimination half-life.<sup>1</sup> Due to concerns regarding the potential for greater ketorolac toxicities resulting from increased ketorolac exposure with probenecid, the combination is contraindicated.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Sprix (ketorolac). Shirley, NY: American Regent, Inc., 1/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5962":"<p><b>Title</b> Nonsteroidal Anti-Inflammatory Agents / Ketorolac (Nasal)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ketorolac (Nasal) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of nasal ketorolac with other nonsteroidal anti-inflammatory agents or aspirin should be avoided.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> Per nasal ketorolac prescribing information, use of ketorolac with other nonsteroidal anti-inflammatory agents (NSAIDs) or aspirin should generally be avoided due to the risk of additive or synergistic NSAID toxicities (e.g., GI bleeding, renal dysfunction, etc.).<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Sprix (ketorolac). Shirley, NY: American Regent, Inc., 1/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5963":"<p><b>Title</b> Aspirin / Ketorolac (Nasal)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ketorolac (Nasal) may enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Ketorolac (Nasal) may diminish the cardioprotective effect of Aspirin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of nasal ketorolac with other nonsteroidal anti-inflammatory agents or aspirin should be avoided.</p> \n<p><b>Discussion</b> Per nasal ketorolac prescribing information, use of ketorolac with other nonsteroidal anti-inflammatory agents (NSAIDs) or aspirin should generally be avoided due to the risk of additive or synergistic NSAID toxicities (e.g., GI bleeding, renal dysfunction, etc.).<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Sprix (ketorolac). Shirley, NY: American Regent, Inc., 1/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5965":"<p><b>Title</b> Neuromuscular-Blocking Agents (Nondepolarizing) / Ketorolac (Nasal)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ketorolac (Nasal) may enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Be aware that cases of apnea have been reported with ketorolac use in patients also receiving nondepolarizing neuromuscular blockers. Use this combination with caution, and monitor closely for episodes of apnea.</p>\n<div>\n <p><b>Neuromuscular-Blocking Agents (Nondepolarizing) Interacting Members</b> Atracurium, Cisatracurium, Mivacurium, Pancuronium, Rocuronium, Vecuronium</p>\n</div> \n<p><b>Discussion</b> According to ketorolac prescribing information, cases of apnea have been reported with ketorolac use in patients also receiving nondepolarizing neuromuscular blockers.<sup>1</sup> Use this combination with caution, and monitor closely for episodes of apnea.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Sprix (ketorolac). Shirley, NY: American Regent, Inc., 1/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5966":"<p><b>Title</b> NiMODipine / FLUoxetine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> FLUoxetine may increase the serum concentration of NiMODipine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased nimodipine pharmacologic effects with concomitant use of fluoxetine. Nimodipine dose reductions may be necessary.</p> \n<p><b>Discussion</b> Following coadministration of nimodipine (30 mg TID x3 months) and fluoxetine (20 mg/day x14 days) to 39 elderly patients, plasma concentrations of nimodipine increased 50% while those of fluoxetine decreased 20% and those of norfluoxetine were not significantly affected.<sup>1</sup> The mechanism for this apparent interaction is unclear. Both drugs are highly protein bound and might displace each other from their binding proteins. In vivo, fluoxetine did not appear to inhibit CYP3A4,<sup>2</sup> the isoenzyme primarily responsible for nimodipine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Product Monograph. Nimotop (nimodipine). Toronto, Ontario: Bayer Inc., April 2009.</p>\n<p>2. Prescribing information. Prozac (fluoxetine). Indianapolis, IN: Eli Lilly and Company, April 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5967":"<p><b>Title</b> Boceprevir / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Boceprevir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concomitant use of boceprevir and carbamazepine should be avoided due to a possible risk of diminished virologic response.</p> \n<p><b>Discussion</b> Boceprevir prescribing information lists coadministration with carbamazepine as contraindicated due to a risk of decreased boceprevir concentrations and loss of virologic response.<sup>1</sup> The presumed primary mechanism of interaction between these agents is carbamazepine induction of CYP3A4/5 mediated boceprevir metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 5/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5968":"<p><b>Title</b> Boceprevir / PHENobarbital</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> PHENobarbital may decrease the serum concentration of Boceprevir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concomitant use of boceprevir and phenobarbital should be avoided due to a possible risk of diminished virologic response.</p> \n<p><b>Discussion</b> Boceprevir prescribing information lists coadministration with phenobarbital as contraindicated due to a risk of decreased boceprevir concentrations and loss of virologic response.<sup>1</sup> The presumed primary mechanism of interaction between these agents is phenobarbital induction of CYP3A4/5 mediated boceprevir metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 5/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5969":"<p><b>Title</b> Boceprevir / Primidone</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Primidone may decrease the serum concentration of Boceprevir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concomitant use of boceprevir and primidone should be avoided due to a possible risk of diminished virologic response.</p> \n<p><b>Discussion</b> Boceprevir prescribing information lists coadministration with phenobarbital (an active metabolite of primidone) as contraindicated due to a risk of decreased boceprevir concentrations and loss of virologic response.<sup>1</sup> Therefore, coadministration with primidone should also be avoided. The presumed primary mechanism of interaction between these agents is phenobarbital induction of CYP3A4/5 mediated boceprevir metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 5/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5970":"<p><b>Title</b> Boceprevir / Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Phenytoin may decrease the serum concentration of Boceprevir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concomitant use of boceprevir and phenytoin should be avoided due to a possible risk of diminished virologic response.</p> \n<p><b>Discussion</b> Boceprevir prescribing information lists coadministration with phenytoin as contraindicated due to a risk of decreased boceprevir concentrations and loss of virologic response.<sup>1</sup> The presumed primary mechanism of interaction between these agents is phenytoin induction of CYP3A4/5 mediated boceprevir metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 5/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5971":"<p><b>Title</b> Boceprevir / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Boceprevir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concomitant use of boceprevir and rifampin should be avoided due to a possible risk of diminished virologic response.</p> \n<p><b>Discussion</b> Boceprevir prescribing information lists coadministration with rifampin as contraindicated due to a risk of decreased boceprevir concentrations and loss of virologic response.<sup>1</sup> The presumed primary mechanism of interaction between these agents is rifampin induction of CYP3A4/5 mediated boceprevir metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 5/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5972":"<p><b>Title</b> Dihydroergotamine / Boceprevir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Boceprevir may increase the serum concentration of Dihydroergotamine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concomitant use of boceprevir and dihydroergotamine should be avoided due to a possible increased risk of ergot toxicity (peripheral vasospasm, ischemia of extremities and other tissues).</p> \n<p><b>Discussion</b> Boceprevir prescribing information lists coadministration with dihydroergotamine as contraindicated due to a risk of increased dihydroergotamine concentrations and ergot toxicity (peripheral vasospasm, ischemia of extremities and other tissues).<sup>1</sup> The presumed primary mechanism of interaction between these agents is boceprevir inhibition of CYP3A4 mediated dihydroergotamine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 5/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5973":"<p><b>Title</b> Methylergonovine / Boceprevir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Boceprevir may increase the serum concentration of Methylergonovine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concomitant use of boceprevir and methylergonovine should be avoided due to a possible increased risk of ergot toxicity (peripheral vasospasm, ischemia of extremities and other tissues).</p> \n<p><b>Discussion</b> Boceprevir prescribing information lists coadministration with methylergonovine as contraindicated due to a risk of increased methylergonovine concentrations and ergot toxicity (peripheral vasospasm, ischemia of extremities and other tissues).<sup>1</sup> The presumed primary mechanism of interaction between these agents is boceprevir inhibition of CYP3A4 mediated methylergonovine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 5/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5974":"<p><b>Title</b> Ergotamine / Boceprevir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Boceprevir may increase the serum concentration of Ergotamine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concomitant use of boceprevir and ergotamine should be avoided due to a possible increased risk of ergot toxicity (peripheral vasospasm, ischemia of extremities and other tissues).</p> \n<p><b>Discussion</b> Boceprevir prescribing information lists coadministration with ergotamine as contraindicated due to a risk of increased ergotamine concentrations and ergot toxicity (peripheral vasospasm, ischemia of extremities and other tissues).<sup>1</sup> The presumed primary mechanism of interaction between these agents is boceprevir inhibition of CYP3A4 mediated ergotamine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 5/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5975":"<p><b>Title</b> Cisapride / Boceprevir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Boceprevir may increase the serum concentration of Cisapride. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concomitant use of boceprevir and cisapride should be avoided due to a possible increased risk of cisapride induced cardiac arrhythmia.</p> \n<p><b>Discussion</b> Boceprevir prescribing information lists coadministration with cisapride as contraindicated due to a risk of increased cisapride concentrations and cardiac arrhythmia.<sup>1</sup> The presumed primary mechanism of interaction between these agents is boceprevir inhibition of CYP3A4 mediated cisapride metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 5/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5976":"<p><b>Title</b> Boceprevir / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Boceprevir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concomitant use of boceprevir and St John's wort should be avoided due to a possible risk of diminished virologic response.</p> \n<p><b>Discussion</b> Boceprevir prescribing information lists coadministration with St. John's wort as contraindicated due to a risk of decreased boceprevir concentrations and loss of virologic response.<sup>1</sup> The presumed primary mechanism of interaction between these agents is St. John's wort induction of CYP3A4/5 mediated boceprevir metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 5/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5977":"<p><b>Title</b> Simvastatin / Boceprevir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Boceprevir may increase the serum concentration of Simvastatin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concomitant use of boceprevir and simvastatin should be avoided due to a possible increased risk of myopathy.</p> \n<p><b>Discussion</b> Boceprevir prescribing information lists coadministration with simvastatin as contraindicated due to a risk of increased simvastatin concentrations and myopathy.<sup>1</sup> The presumed primary mechanism of interaction between these agents is boceprevir inhibition of CYP3A4 mediated simvastatin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 5/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5978":"<p><b>Title</b> Lovastatin / Boceprevir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Boceprevir may increase the serum concentration of Lovastatin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concomitant use of boceprevir and lovastatin should be avoided due to a possible increased risk of myopathy.</p> \n<p><b>Discussion</b> Boceprevir prescribing information lists coadministration with lovastatin as contraindicated due to a risk of increased lovastatin concentrations and myopathy.<sup>1</sup> The presumed primary mechanism of interaction between these agents is boceprevir inhibition of CYP3A4 mediated lovastatin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 5/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5979":"<p><b>Title</b> Drospirenone / Boceprevir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Boceprevir may increase the serum concentration of Drospirenone. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concomitant use of boceprevir and drospirenone should be avoided due to a possible increased risk of drospirenone toxicity (including hyperkalemia). Further, patients should not rely on systemic hormonal contraceptives for contraception during treatment with boceprevir. Patients receiving combination regimens containing ribavirin should use two alternative effective means of contraception.</p> \n<p><b>Discussion</b> Boceprevir prescribing information lists coadministration with drospirenone as contraindicated due to a risk of increased drospirenone concentrations and toxicity (including hyperkalemia).<sup>1</sup> In a clinical study, drospirenone (3 mg daily for 14 days) maximum concentration (Cmax) and AUC were increased by 57% and 99%, respectively, during treatment with boceprevir (800 mg 3 times daily for 7 days).<sup>1</sup> In the same study, ethinyl estradiol (0.02 mg daily for 14 days) Cmax was unchanged and AUC was decreased by an average of 24% during boceprevir. The presumed primary mechanism of the boceprevir-drospirenone interaction is boceprevir inhibition of CYP3A4 mediated drospirenone metabolism. The mechanism of interaction between boceprevir and ethinyl estradiol is unknown. The impact of boceprevir treatment on concentrations of other estrogen and progestin derivatives is unknown, but similar caution is advised. Boceprevir prescribing information recommends that hormonal contraceptives not be relied on for contraception during boceprevir treatment.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 5/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5980":"<p><b>Title</b> Sildenafil / Boceprevir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: When sildenafil is being used to treat pulmonary arterial hypertension, concurrent use with boceprevir is contraindicated. When used to treat erectile dysfunction, a sildenafil dose reduction is required if used with boceprevir.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Boceprevir may increase the serum concentration of Sildenafil. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid sildenafil when used for treatment of pulmonary arterial hypertension in patients receiving boceprevir. Sildenafil for erectile dysfunction should be limited to 25 mg every other day with close monitoring for symptoms of sildenafil toxicity (including hypotension, visual changes, syncope, and priapism).</p> \n<p><b>Discussion</b> Boceprevir prescribing information lists coadministration with sildenafil, when used for treatment of pulmonary arterial hypertension, as contraindicated due to a risk for increased sildenafil concentrations and toxicity (hypotension, visual changes, syncope, priapism).<sup>1</sup> When sildenafil is used for erectile dysfunction in combination with boceprevir, boceprevir prescribing information specifies a maximum sildenafil dose of 25 mg every other day. The presumed primary mechanism of interaction between these agents is boceprevir inhibition of CYP3A4 mediated sildenafil metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 5/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5981":"<p><b>Title</b> Tadalafil / Boceprevir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: When tadalafil is being used to treat pulmonary arterial hypertension, concurrent use with boceprevir is contraindicated. When used to treat erectile dysfunction, a tadalafil dose reduction is required if used with boceprevir.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Boceprevir may increase the serum concentration of Tadalafil. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Recommendations regarding use of tadalafil in patients also receiving boceprevir may vary based on indication and/or international labeling. <b>Treatment of pulmonary arterial hypertension:</b> Because of the requirement for higher doses of tadalafil when used to treat pulmonary arterial hypertension, the concurrent use of tadalafil with a strong CYP3A4 inhibitor (such as boceprevir) should be avoided. <b>For treatment of erectile dysfunction (ED) and/or benign prostatic hyperplasia (BPH):</b> This recommendation varies based on international labeling. For patients also receiving strong CYP3A4 inhibitors (such as boceprevir), U.S. product labeling recommends limiting tadalafil to a maximum of 2.5 mg/day (for once daily use) or 10 mg per 72 hours (for use as needed to treat ED). The Canadian product labeling recommends a tadalafil dose of 2.5-5 mg/day (for once daily use to treat ED), or 10 mg at minimum intervals of 48 hours and a maximum of 3 doses/week, with the option of increasing tadalafil to 20 mg if the lower dose is tolerated but ineffective (for use as needed). Canadian product labeling does not include BPH as an indication for tadalafil use. <br><br>If using tadalafil concurrently with strong CYP3A4 inhibitors (such as boceprevir), monitor more closely for signs and symptoms of tadalafil toxicity (examples may include headache, dyspepsia, myalgia, flushing, priapism, and cardiovascular complications).</p> \n<p><b>Discussion</b> Specific clinical data regarding use of this combination are not available, but data with ketoconazole, which is also a strong CYP3A4 inhibitor, do support the existence of a significant interaction. Compared to control subjects, tadalafil AUC was increased by an average of 312% (20 mg dose) and 107% (10 mg dose) in patients taking ketoconazole daily (400 mg/day or 200 mg/day, respectively). Tadalafil maximum serum concentrations (Cmax) were also increased by 22% and 15%, respectively.<sup>1,2,3,4</sup> <br><br>The mechanism for this suspected interaction is boceprevir inhibition of tadalafil metabolism. Tadalafil is primarily a CYP3A4 substrate,<sup>1</sup> and boceprevir is a strong CYP3A4 inhibitor.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Cialis (tadalafil). Indianapolis, IN: Eli Lilly and Company, October 2011.</p>\n<p>2. Product monograph. Cialis (tadalafil). Toronto, Ontario, Canada: Eli Lilly Canada Inc., March 2009.</p>\n<p>3. Prescribing information. Adcirca (tadalafil). Indianapolis, IN: Eli Lilly and Company, March 2012.</p>\n<p>4. Product monograph. Adcirca (tadalafil). Toronto, Ontario, Canada: Eli Lilly Canada Inc., May 2010.</p>\n<p>5. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 5/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5982":"<p><b>Title</b> Vardenafil / Boceprevir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Boceprevir may increase the serum concentration of Vardenafil. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Limit vardenafil maximum dose to 2.5 mg every 24 hours and monitor closely for symptoms of vardenafil toxicity (including hypotension, visual changes, syncope, and priapism) during treatment with boceprevir.</p> \n<p><b>Discussion</b> Boceprevir prescribing information recommends limiting the dose of vardenafil to 2.5 mg every 24 hours during boceprevir treatment due to a risk of increased vardenafil concentrations and toxicity (hypotension, visual changes, syncope, priapism).<sup>1</sup> The presumed primary mechanism of interaction between these agents is boceprevir inhibition of CYP3A4 mediated vardenafil metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 5/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5983":"<p><b>Title</b> Pimozide / Boceprevir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Boceprevir may increase the serum concentration of Pimozide. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concomitant use of boceprevir and pimozide should be avoided due to a possible increased risk of pimozide induced cardiac arrhythmia.</p> \n<p><b>Discussion</b> Boceprevir prescribing information lists coadministration with pimozide as contraindicated due to a risk of increased pimozide concentrations and cardiac arrhythmia.<sup>1</sup> The presumed primary mechanism of interaction between these agents is boceprevir inhibition of CYP3A4 mediated pimozide metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 5/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5985":"<p><b>Title</b> Midazolam / Boceprevir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): Oral midazolam should be avoided in boceprevir treated patients. Intravenous midazolam may pose a lower risk, but dose reductions should be considered and patients should be closely monitored for toxicity.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Boceprevir may increase the serum concentration of Midazolam. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid oral midazolam in patients receiving boceprevir. If intravenous midazolam is used, consider lower doses and monitor closely for symptoms of toxicity (including prolonged sedation and respiratory depression).</p> \n<p><b>Discussion</b> In a study mentioned in boceprevir prescribing information, coadministration of boceprevir (800 mg three times daily for 6 days) with midazolam (4 mg single oral dose) increased midazolam maximum concentration and AUC by 2.8 fold and 5.3 fold, respectively.<sup>1</sup> Administration of oral midazolam with boceprevir is listed as contraindicated. Intravenous midazolam use may pose a lower risk, but dose reductions should be considered and patients should be monitored for symptoms of toxicity (including prolonged sedation and respiratory depression).<sup>1</sup> The presumed primary mechanism of interaction between these agents is boceprevir inhibition of CYP3A4 mediated midazolam metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 5/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5986":"<p><b>Title</b> Amiodarone / Boceprevir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: This combination is contraindicated according to the boceprevir Canadian product monograph but not according to the boceprevir U.S. prescribing information.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Boceprevir may increase the serum concentration of Amiodarone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased amiodarone concentration (if testing is available) and pharmacologic effect in patients receiving boceprevir. This combination is contraindicated according to the Canadian boceprevir product monograph but not according to the U.S. prescribing information.</p> \n<p><b>Discussion</b> Prescribing information for boceprevir recommends cautious use in combination with amiodarone.<sup>1</sup> Monitor for increased amiodarone concentration (if testing is available) and pharmacologic effect. The presumed primary mechanism of interaction between these agents is boceprevir inhibition of CYP3A4 mediated amiodarone metabolism.<br><br>Of note, this combination is contraindicated according to the Canadian boceprevir product monograph,<sup>2</sup> but not according to the U.S. prescribing information.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 5/2011.</p>\n<p>2. Product monograph. Victrelis (boceprevir). Kirkland, QC, Canada: Merck Canada Inc., January 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5987":"<p><b>Title</b> Bepridil / Boceprevir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Boceprevir may increase the serum concentration of Bepridil. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased bepridil concentration (if testing is available) and pharmacologic effect in patients receiving boceprevir.</p> \n<p><b>Discussion</b> Prescribing information for boceprevir recommends cautious use in combination with bepridil.<sup>1</sup> Monitor for increased bepridil concentration (if testing is available) and pharmacologic effect. The mechanism of this possible interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 5/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5988":"<p><b>Title</b> Flecainide / Boceprevir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Boceprevir may increase the serum concentration of Flecainide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased flecainide concentration (if testing is available) and pharmacologic effect in patients receiving boceprevir.</p> \n<p><b>Discussion</b> Prescribing information for boceprevir recommends cautious use in combination with flecainide.<sup>1</sup> Monitor for increased flecainide concentration (if testing is available) and pharmacologic effect. The mechanism of this possible interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 5/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5989":"<p><b>Title</b> Propafenone / Boceprevir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: This combination is contraindicated according to the boceprevir Canadian product monograph but not according to the boceprevir U.S. prescribing information.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Boceprevir may increase the serum concentration of Propafenone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased propafenone concentration (if testing is available) and pharmacologic effect in patients receiving boceprevir. This combination is contraindicated according to the Canadian boceprevir product monograph but not according to the U.S. prescribing information.</p> \n<p><b>Discussion</b> Prescribing information for boceprevir recommends cautious use in combination with propafenone.<sup>1</sup> Monitor for increased propafenone concentration (if testing is available) and pharmacologic effect. The presumed primary mechanism of interaction between these agents is boceprevir inhibition of CYP3A4 mediated propafenone metabolism.<br><br>Of note, this combination is contraindicated according to the Canadian boceprevir product monograph,<sup>2</sup> but not according to the U.S. prescribing information.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 5/2011.</p>\n<p>2. Product monograph. Victrelis (boceprevir). Kirkland, QC, Canada: Merck Canada Inc., January 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5990":"<p><b>Title</b> QuiNIDine / Boceprevir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: This combination is contraindicated according to the boceprevir Canadian product monograph but not according to the boceprevir U.S. prescribing information.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Boceprevir may increase the serum concentration of QuiNIDine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased quinidine concentration (if testing is available) and pharmacologic effect in patients receiving boceprevir. This combination is contraindicated according to the Canadian boceprevir product monograph but not according to the U.S. prescribing information.</p> \n<p><b>Discussion</b> Prescribing information for boceprevir recommends cautious use in combination with quinidine.<sup>1</sup> Monitor for increased quinidine concentration (if testing is available) and pharmacologic effect. The presumed primary mechanism of interaction between these agents is boceprevir inhibition of CYP3A4 mediated quinidine metabolism.<br><br>Of note, this combination is contraindicated according to the Canadian boceprevir product monograph,<sup>2</sup> but not according to the U.S. prescribing information.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 5/2011.</p>\n<p>2. Product monograph. Victrelis (boceprevir). Kirkland, QC, Canada: Merck Canada Inc., January 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5991":"<p><b>Title</b> Digoxin / Boceprevir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Boceprevir may increase the serum concentration of Digoxin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> In patients initiating digoxin during boceprevir treatment, initiate at the lowest possible digoxin dose, monitor serum digoxin concentrations, and titrate carefully due to a possible risk of elevated digoxin concentrations.</p> \n<p><b>Discussion</b> Boceprevir prescribing information recommends that boceprevir treated patients initiating digoxin should be started at the lowest possible digoxin dose, due to a risk of elevated digoxin concentrations.<sup>1</sup> Titrate carefully and monitor serum digoxin concentration. The mechanism of this possible interaction is unknown. Boceprevir inhibition of P-glycoprotein mediated digoxin transport may contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 5/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5992":"<p><b>Title</b> Warfarin / Boceprevir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Boceprevir may decrease the serum concentration of Warfarin. Boceprevir may increase the serum concentration of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor international normalized ratio (INR) closely when boceprevir and warfarin are given concomitantly, due to a possible risk of altered warfarin concentrations.</p> \n<p><b>Discussion</b> A case report describes a 73-year-old man on warfarin (15 mg per week) with stable INRs who experienced subtherapeutic INRs requiring a 75% increase in warfarin dose (26.5 mg per week) after initiation of boceprevir.<sup>1</sup> After boceprevir discontinuation, his warfarin dose had to be reduced to 23.75 mg per week over the course of 2 weeks to maintain a therapeutic INR.<sup>1</sup><br><br>Boceprevir prescribing information recommends close monitoring of the INR in patients receiving boceprevir and warfarin concomitantly, due to possible increases or decreases in warfarin concentration.<sup>2</sup> The mechanism of this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Tsiattalos AS, Patel A. Warfarin and boceprevir interaction causing subtherapeutic international normalized ratio: a case report. <i>J Med Case Rep</i>. 2014;8:433. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25515435\">[PubMed 25515435]</a></p>\n<p>2. Victrelis (boceprevir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5993":"<p><b>Title</b> Desipramine / Boceprevir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Boceprevir may increase the serum concentration of Desipramine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider lower doses of desipramine in patients treated with boceprevir and monitor for symptoms of desipramine toxicity (including dizziness, hypotension and syncope), due to a possible increase in desipramine concentrations.</p> \n<p><b>Discussion</b> Boceprevir prescribing information recommends cautious use in combination with desipramine.<sup>1</sup> Consider lower desipramine doses and monitor for symptoms of desipramine toxicity (dizziness, hypotension, syncope) in patients who receive both drugs. The mechanism of this possible interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 5/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5995":"<p><b>Title</b> Itraconazole / Boceprevir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Itraconazole may increase the serum concentration of Boceprevir. Boceprevir may increase the serum concentration of Itraconazole. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Limit maximum adult itraconazole dose to 200 mg daily in patients receiving boceprevir, due to a possible increase in itraconazole concentrations.</p> \n<p><b>Discussion</b> Boceprevir prescribing information recommends limiting the maximum adult itraconazole dose to 200 mg daily in patients receiving boceprevir, due to a possible increase in itraconazole concentrations.<sup>1</sup> Additionally, in a clinical study, coadministration of the related azole antifungal agent ketoconazole (400 mg twice daily for 6 days) with boceprevir (400 mg single dose) increased the maximum concentration and AUC of boceprevir by 41% and 131%, respectively.<sup>1</sup> <br><br>Itraconazole and boceprevir likely both inhibit the CYP3A4 mediated metabolism of the other drug. Itraconazole may also inhibit P-glycoprotein mediated boceprevir transport.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 5/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5996":"<p><b>Title</b> Posaconazole / Boceprevir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Posaconazole may increase the serum concentration of Boceprevir. Boceprevir may increase the serum concentration of Posaconazole. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients receiving boceprevir and posaconazole for increased systemic effects of both drugs, due to a possible risk of increased drug concentrations.</p> \n<p><b>Discussion</b> Prescribing information for boceprevir indicates that concentrations of both boceprevir and posaconazole may become elevated during concomitant use.<sup>1</sup> Posaconazole likely inhibits CYP3A4 mediated boceprevir metabolism. The mechanism by which boceprevir may increase posaconazole concentrations is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 5/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5997":"<p><b>Title</b> Voriconazole / Boceprevir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Boceprevir may increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Boceprevir. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients receiving boceprevir and voriconazole for increased systemic effects of both drugs, due to a possible risk of increased drug concentrations.</p> \n<p><b>Discussion</b> Prescribing information for boceprevir indicates that concentrations of both boceprevir and voriconazole may become elevated during concomitant use.<sup>1</sup> Both drugs may inhibit CYP3A4 mediated metabolism of the other, although CYP3A4 is not the primary metabolic pathway for either drug.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 5/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5998":"<p><b>Title</b> Ketoconazole (Systemic) / Boceprevir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ketoconazole (Systemic) may increase the serum concentration of Boceprevir. Boceprevir may increase the serum concentration of Ketoconazole (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Limit maximum adult ketoconazole dose to 200 mg daily in patients receiving boceprevir, due to a possible increase in ketoconazole concentrations.</p> \n<p><b>Discussion</b> Boceprevir prescribing information recommends limiting the maximum adult ketoconazole dose to 200 mg daily in patients receiving boceprevir, due to a possible increase in ketoconazole concentrations.<sup>1</sup> Additionally, in a clinical study, coadministration of ketoconazole (400 mg twice daily for 6 days) with boceprevir (400 mg single dose) increased the maximum concentration and AUC of boceprevir by 41% and 131%, respectively.<sup>1</sup> <br><br>Ketoconazole and boceprevir likely both inhibit the CYP3A4 mediated metabolism of the other drug. Ketoconazole may also inhibit P-glycoprotein mediated boceprevir transport.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 5/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5999":"<p><b>Title</b> Rifabutin / Boceprevir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Rifabutin may decrease the serum concentration of Boceprevir. Boceprevir may increase the serum concentration of Rifabutin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of boceprevir and rifabutin.</p> \n<p><b>Discussion</b> Boceprevir prescribing information recommends avoiding the combination of rifabutin and boceprevir, as safe and effective doses for this combination have not been established.<sup>1</sup> Boceprevir may increase rifabutin concentrations via inhibition of CYP3A4 mediated rifabutin metabolism, and rifabutin may decrease boceprevir concentrations via induction of CYP3A4 mediated boceprevir metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 5/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}